Document:

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                                                  Exhibit 10.13

      THIS AGREEMENT made in duplicate as of this 14 day of June, 2004.

BETWEEN:

                                    MDS NORDION, a division of MDS (Canada) Inc.
                                    having a place of business at
                                    447 March Road
                                    Ottawa, Ontario, Canada K2K1X8

                                    ("Nordion")

AND:

                                        MOLECULAR INSIGHT PHARMACEUTICALS, INC.
                                        having a place of business at
                                        160 Second Street
                                        Cambridge Massachusetts, 02142 USA

                                        ("Molecular Insight Pharmaceuticals")

WHEREAS:

I.    Molecular Insight Pharmaceuticals is the owner or licensee of a certain
      compound known as BMIPP (as defined), a heart diagnostic imaging agent;

II.   Nordion has expertise in the development of pharmaceutical processes and
      radiolabelling of compounds;

III.  Molecular Insight Pharmaceuticals has developed techniques and
      demonstrated an ability to label Precursor with 1-123 to form BMIPP;

IV.   Molecular Insight Pharmaceuticals desires that Nordion undertake at its
      facility a development program based upon Molecular Insight
      Pharmaceutical's technique which will allow Molecular Insight
      Pharmaceuticals' Precursor to be labeled with 1-123 to form BMIPP;

V.    Molecular Insight Pharmaceuticals desires that Nordion establish a
      facility at its site in Vancouver, British Columbia, to produce and supply
      BMIPP for use in support of Molecular Insight Pharmaceuticals' Phase III
      Clinical Trials and in support of Molecular Insight Pharmaceuticals' drug
      submission to the FDA.

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties hereto agree as follows:

<PAGE>

                                       2

                             ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement:

1.1   "Affiliate" shall mean an entity or person which controls, is controlled
      by or is under common control with either party. For purposes of this
      Section 1.1 control shall mean (a) in the case of corporate entities, the
      direct or indirect ownership of more than one-half of the stock or
      participating shares entitled to vote for the election of directors, and
      (b) in the case of a partnership, the power to direct the management and
      policies of such partnership.

1.2   "BMIPP" shall mean a pharmaceutical product containing 1-123 labeled
      Precursor in diagnostic dosage form for cardiac imaging.

1.3   "Background Technology" shall mean all Nordion proprietary technology
      existing prior to the Effective Date, including patents, copyright,
      know-how, techniques, methods, processes and trade secrets which Nordion
      owns or which is licensed to Nordion and, in each case, which is in
      existence in the form of a writing, prototype or can otherwise be
      demonstrated to be the property of Nordion prior to the Effective Date.

1.4   "Batch" shall mean a production batch of BMIPP manufactured under this
      Agreement.

1.5   "Clinical Trial Batch Size" shall have the meaning attributed in Section
      4.1.

1.6   "Clinical Trials" shall mean Phase III human trials for clinical
      development of BMIPP in the United States.

1.7   "Commercial Phase" shall mean the period of supply of BMIPP commencing
      after NDA regulatory approval has been received in the United States by
      Molecular Insight Pharmaceuticals, from the FDA.

1.8   "Current Good Manufacturing Practices" or "cGMP(s)" shall mean the good
      manufacturing practices required by the FDA and as set forth in the FD&C
      or FDA rules and regulations for the manufacturing, testing and quality
      control of pharmaceutical materials as applied to compounds, which
      practices are current on the Effective Date of this Agreement and may be
      supplemented, amended or modified from time to time.

1.9   "Development Phase" shall mean the period commencing from the Effective
      Date until completion of the activities described in Schedule A.

1.10  "Effective Date" shall mean the date first above written.
<PAGE>
                                        3

1.11  "FDA" shall mean the United States Food and Drug Administration.

1.12  "FD&C" shall mean the United States Federal Food, Drug and Cosmetic Act,
      as amended.

1.13  "Facility" shall mean the facility to be established by Nordion at its
      manufacturing site in Vancouver, British Columbia as described in Schedule
      B and pursuant to cGMPs, to be used for the production of BMIPP for
      diagnostic applications and purposes.

1.14  "IND" shall mean an Investigational New Drug Application as defined by the
      rules and regulations promulgated under the FD&C and U.S. Public Health
      Service Act and any supplements, modifications or amendments thereunder.

1.15  "Isotope" or "I-123" shall mean Iodine 123.

1.16  "Master Validation Plan" shall mean the program mutually agreed to by the
      parties by which documented evidence provides assurance that the Process
      will consistently produce BMIPP that meets Specifications.

1.17  "NDA" shall mean a new drug application as defined in the rules and
      regulations promulgated under the FD&C and U.S. Public Health Service Act,
      as supplemented, modified or amended from time to time.

1.18  "Precursor" shall mean (beta)-methyl-p-iodophenyl-pentadecanoic acid
      specified in Schedule C and produced pursuant to cGMPs.

1.19  "Process" shall mean the method of formulation, dispensing, and testing of
      the BMIPP developed under this Agreement and in compliance with cGMPS.

1.20  "Reference Standards" shall mean the cGMP compliant compounds as specified
      in Schedule D.

1.21  "Specification(s)" shall mean those final specifications for BMIPP as set
      out in Schedule E, as amended by mutual agreement of the parties from time
      to time.

                              ARTICLE 2 - PURPOSE

2.1   Scope and Object

      The scope and object of this Agreement is to carry out the development of
      the Process in accordance with the responsibilities and obligations
      attributed to each of the parties as set out in this Agreement. In
      addition,

<PAGE>

                                        4

      this Agreement shall provide for the establishment of a Facility to be
      utilized, amongst other purposes, in the production and supply of BMIPP as
      required in support of Molecular Insight Pharmaceuticals' BMIPP Phase III
      Clinical Trial and NDA submission to the FDA.

                         ARTICLE 3 - DEVELOPMENT PHASE

3.1   Development Activities

      During the Development Phase, Nordion and Molecular Insight
      Pharmaceuticals shall carry out their respective obligations described and
      attributed in Schedule A, it being understood that some activities may be
      reasonably delayed to the extent that such activity is premised on the
      work or provision of data, information or technology by the other party.
      It is understood and acknowledged that due to the developmental nature of
      the activities to be carried out during the Development Phase, the time
      for completion and sequence for carrying out the activities as set out in
      Schedule A shall serve as a guide. Each party shall use their commercially
      reasonable best efforts in order to carry out, in a timely manner, their
      respective obligations and responsibilities set out in Schedule A.

      If either party, acting in good faith, materially fails to satisfy any
      milestone or is unable to meet such milestone in accordance with the
      timing set out in Schedule A, such party shall provide written notice
      thereof to the other party and the parties shall determine a reasonable
      corrective action plan and revised milestone schedule. If the parties are
      unable to determine a reasonable corrective action plan and revised
      milestone schedule, the parties may submit such matter to binding
      arbitration in Vancouver, British Columbia, pursuant to and conducted
      under the International Commercial Arbitration Act of British Columbia,
      which arbitration shall be conducted before a single arbitrator possessing
      appropriate industry experience as selected by the parties. If the parties
      cannot agree on a single arbitrator, the arbitrator shall be appointed in
      accordance with the International Commercial Arbitration Act of British
      Columbia. The decision of the arbitrators shall be final and binding.

      The parties acknowledge and agree that Schedule A may be amended during
      the course of the Development Phase to accommodate unforeseen events and
      results. All such changes to Schedule A shall be made by written agreement
      of the parties. If any change to Schedule A materially impacts the scope
      of work to be provided by Nordion, Nordion will provide a written estimate
      of the increase in hours of work at the rates set forth in Section 6.3,
      which must be approved in advance by Molecular Insight Pharmaceuticals. No
      work on such scope change shall be carried out by

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       5

      Nordion prior to Nordion's receipt of Molecular Insight Pharmaceuticals'
      written approval of such change.

      The parties, upon signing this Agreement, shall each designate a program
      manager, who shall be responsible for coordinating communication and
      monitoring performance under this Agreement. The program managers shall
      meet monthly, in person or by telephone, for the purpose of reviewing the
      status of the project, assessing progress against the milestones and
      activities set forth in Schedule A, and determining the percentage of each
      milestone completed and the payments earned, if any, in connection with
      each milestone. Minutes of meetings shall be prepared, maintained and
      provided to each of the parties.

3.2   Development Phase Work

      In consideration of Nordion performing the Development Phase services,
      Molecular Insight Pharmaceuticals shall pay Nordion in accordance with the
      rates set out in Schedule F, which schedule includes amounts payable upon
      achievement of milestones as well as amounts payable for each Batch
      produced and supplied by Nordion hereunder. All amounts due Nordion shall
      be paid by Molecular Insight Pharmaceuticals within thirty (30) days of
      the date appearing on Nordion's invoice. Such invoice shall, unless
      otherwise agreed, be payable in United States dollars.

3.3   Facility Program

      In consideration of Nordion establishing the Facility, Molecular Insight
      Pharmaceuticals will pay to Nordion a non-reimbursable facility fee of
      [**********************] United States dollars (US $[********]) upon
      execution of this Agreement.

      After the Facility is completed, Nordion shall, in consultation with
      Molecular Insight Pharmaceuticals, develop and implement a Master
      Validation Plan for the Facility that will allow the production of BMIPP
      under cGMPs in the volumes required by Molecular Insight Pharmaceuticals
      for Phase III clinical supply as described in Section 4.1. The costs of
      preparation, development and implementation of the Master Validation Plan
      will be borne by Nordion. Prior to implementation, both parties shall in
      writing approve the Master Validation Plan. Nordion shall ensure that the
      Facility is available for the production of BMIPP for supply to Molecular
      Insight Pharmaceuticals on a priority basis at least three days per week
      to be mutually agreed between the parties.

3.4   Repairs and Maintenance

<PAGE>

                                        6

      After the Facility is established, Nordion shall maintain such Facility in
      satisfactory operating condition as required by the Specifications,
      Process and cGMPs, and all other applicable laws, regulations, rules or
      orders. The cost of repairs, preventive maintenance and service contracts
      for the Facility shall be borne by Nordion.

3.5   Commercial Phase Negotiations

      Within thirty (30) days after completion of Milestone 2 under the
      Development Phase, the parties shall for a period of at least sixty (60)
      days enter into good faith negotiations for the supply of BMIPP to
      Molecular Insight Pharmaceuticals, during the Commercial Phase.

              ARTICLE 4 - BATCH SIZE IN SUPPORT OF NDA SUBMISSION

4.1   Clinical Supply Batch Size

      The Batch size for Clinical Trial supply shall be thirty (30) doses of
      BMIPP. The maximum number of vials available for shipment from any Batch
      will be twenty (20) doses with the remainder being retained by Nordion for
      archival and quality assurance testing. BMIPP will be shipped in an
      appropriate lead shield, which will be provided at Nordion's expense. All
      necessary labels for shipment will be provided by Molecular Insight
      Pharmaceuticals and shall meet all applicable regulatory requirements.

                       ARTICLE 5 - GENERAL MANUFACTURE AND
                         SUPPLY OBLIGATIONS OF NORDION

5.1   BMIPP Supply

      Nordion agrees to (i) use the Process to produce Batches of BMIPP that
      meet the Specifications and are manufactured in conformance with cGMPs and
      (ii) ship BMIPP to customers as directed by Molecular Insight
      Pharmaceuticals. Nordion reserves the right to withhold from shipment any
      Batch which does not conform to Specifications. The price of any Batch
      required by Molecular Insight Pharmaceuticals during the term of this
      Agreement shall be as set out in Schedule F. The parties agree that
      Molecular Insight Pharmaceuticals will provide BMIPP at its expense and
      Nordion will supply isotopes and other supplies at its expense.

5.2   Compliance with Law; Handling of BMIPP

      While Precursor, Isotope and BMIPP are in its possession or under its
      control, Nordion shall be responsible for compliance with applicable
      statutory and regulatory requirements in the United States and Canada
      regarding the development, manufacture, handling, storage, labeling,

<PAGE>

                                        7

      packaging, transportation and shipment of the Precursor, Isotope and
      BMIPP.

5.3   Testing and Documentation

      Nordion shall maintain accurate and complete production records with
      respect to the Process, Batches and shipments and Molecular Insight
      Pharmaceuticals shall have access to such records in order to determine
      that each Batch was produced and tested in compliance with the
      Specifications and cGMP requirements.

      The tests and analyses provided in the Specifications as well as the
      nature and form of records may be amended by Nordion from time to time,
      subject to the consent of Molecular Insight Pharmaceuticals, which shall
      not be unreasonably withheld after Nordion shall have delivered to
      Molecular Insight Pharmaceuticals, in writing, an explanation of such
      changes and why they are necessary or advisable.

                               ARTICLE 6 - GENERAL
                  MOLECULAR INSIGHT PHARMACEUTICALS OBLIGATIONS

6.1   Precursor and Reference Standards

      Molecular Insight Pharmaceuticals or, at Molecular Insight
      Pharmaceuticals' discretion its designee, shall provide Precursor and
      Reference Standards to Nordion at no charge, which meets the
      specifications in Schedules C and D in sufficient quantities to permit
      Nordion to meet its obligations hereunder. Nordion shall only use
      Precursor and Reference Standards for the manufacture of BMIPP pursuant to
      this Agreement. Nordion shall store Precursor and Reference Standards in
      accordance with its applicable specifications set out in Schedule C and D
      respectively. Molecular Insight Pharmaceuticals shall at all times retain
      title in and to such materials in Nordion's possession.

6.2   Unavailability or Scarcity of Precursor or Reference Standards

      Molecular Insight Pharmaceuticals will notify Nordion upon Molecular
      Insight Pharmaceuticals becoming aware of a shortage of supply of
      Precursor or Reference Standards, if such shortage will impact the
      manufacture of the BMIPP. Except as set out below, Molecular Insight
      Pharmaceuticals shall not be liable for any delays or shortages in the
      supply of Precursor or Reference Standards, provided however, that any
      such shortages or delays in Precursor or Reference Standards supply will
      excuse Nordion's performance of activities related to such Batch of BMIPP
      only to the extent that Nordion's non-performance was caused by the

<PAGE>
                                       8

      Precursor or Reference Standards supply delay or shortage and only for a
      period of time equal to the delay.

6.3   Additional Compensation to Nordion

      In addition to the amounts set forth in Schedule F, Molecular Insight
      Pharmaceuticals will compensate Nordion based on the rate of one hundred
      and twenty-five United States dollars (US$125.00) per person per hour for
      the time spent by Nordion on the following activities only and upon
      Molecular Insight Pharmaceuticals prior written request:

      (i)   preparing and hosting Facility audits requested by Molecular Insight
            Pharmaceuticals including FDA preaudit inspections;

      (ii)  preparing responses to FDA inquiries and preparation by Nordion of
            information requested by Molecular Insight Pharmaceuticals in
            support of Molecular Insight Pharmaceuticals' BMIPP NDA submission;
            and

      (iii) attending meetings with the FDA.

      Molecular Insight Pharmaceuticals shall reimburse Nordion for all costs
      incurred for travel and accommodation in carrying out the foregoing
      activities. Nordion shall provide an estimate of all such activities to
      Molecular Insight Pharmaceuticals prior to incurring the expenditure.

                          ARTICLE 7 - BMIPP SHIPMENTS

7.1   Orders and Shipments

      During the term of this Agreement, Molecular Insight Pharmaceuticals will
      forward orders to Nordion at its Kanata, Ontario facility by facsimile.
      Each order will set forth the quantity to be produced and shipped, the
      identity of the recipient, delivery destination protocol number, IND
      number, applicable USNRC materials license number and IRS number. Delivery
      of BMIPP to Molecular Insight Pharmaceuticals or as otherwise directed by
      Molecular Insight Pharmaceuticals shall be FOB transport vehicle at
      Nordion's facility in Vancouver, British Columbia. Risk of loss of BMIPP
      shall pass to Molecular Insight Pharmaceuticals at point of delivery.

      During the term of this Agreement Nordion shall use commercially
      reasonable best efforts to meet Molecular Insight Pharmaceuticals' orders
      and delivery requirements. Prior to the first shipment of BMIPP to any
      third party site, Molecular Insight Pharmaceuticals shall obtain from such
      third party and provide to Nordion such third party's license evidencing
      proper legal authority for the receipt and possession of the BMIPP by such
      third party. Molecular Insight Pharmaceuticals shall obtain all approvals,
      licenses and permits required to import BMIPP into the United States.
<PAGE>

                                        9

      Nordion shall make shipping arrangements with AirNet Express or such other
      carrier designated by Nordion and reasonably approved by Molecular Insight
      Pharmaceuticals. All shipping costs incurred to deliver BMIPP shall be
      borne by Molecular Insight Pharmaceuticals.

      Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch
      ordered from Nordion by providing to Nordion at least two (2) business
      days written notice of cancellation prior to the later of commencement of
      production or the scheduled production date. The failure to give notice
      hereunder shall result in Molecular Insight Pharmaceuticals being required
      to pay the full purchase price of such Batch to Nordion. All orders for
      BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received
      by Nordion by the Friday Noon (Eastern time) prior to the week in which
      BMIPP is to be manufactured.

7.2   Warranty/Recall

      Nordion warrants the BMIPP will meet the Specifications and be
      manufactured in accordance with cGMP's and be free from defects in
      material and workmanship for the period from the date of manufacture to
      the expiry date set out on each vial of BMIPP.

      If either party discovers that a Batch of BMIPP does not meet the
      Specifications, then the discovering party shall promptly communicate with
      the other party. If Molecular Insight Pharmaceuticals determines that the
      failure to meet Specifications results from an act, failure to act or
      other fault of Nordion, or agent of Nordion, Nordion will promptly:

      (i) repair or replace such batch of BMIPP; and

      (ii) pay for shipping costs of replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault id due to Nordion and/or its agent, the
      parties will select a mutually acceptable outside consulting firm which
      will be instructed to review the applicable information and data and
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will have the obligations set out in this Section
      and Nordion will pay the fees of such consulting firm. If the consulting
      firm dissents from Molecular Insight Pharmaceuticals' determination or
      determines that the failure to meet Specifications was due to products,
      information or services supplied by Molecular Insight Pharmaceuticals,
      Nordion will not have the obligations set out in this Section with respect
      to the disputed Batch and Molecular Insight Pharmaceuticals will pay the
      fees for such consulting firm.

<PAGE>

                                       10

                               ARTICLE 8 - LICENSE

8.1   Royalty-Free License

      Molecular Insight Pharmaceuticals hereby provides to Nordion a
      nonexclusive, nontransferable, royalty-free license during the term of
      this Agreement to use the patents, data, information and technology
      provided by Molecular Insight Pharmaceuticals relating to BMIPP and the
      radiolabelling of 1-123 with Precursor for the sole purpose of assisting
      Nordion in carrying out its obligations set out in this Agreement.
      Molecular Insight Pharmaceuticals represents and warrants that the
      technology provided by Molecular Insight Pharmaceuticals relating to BMIPP
      allows for BMIPP to be terminally sterilized while still meeting the
      specifications set out in Schedule E.

                  ARTICLE 9 - MOLECULAR INSIGHT PHARMACEUTICALS
                         REPRESENTATIONS AND WARRANTIES

9.1   Molecular Insight Pharmaceuticals' Representations and Warranties

      Molecular Insight Pharmaceuticals represents, warrants and covenants that:

      (i)   it has full right, power and authority to enter into this Agreement;

      (ii)  it is the owner or has the right of use of the patents, data,
            information and technology supplied to Nordion by Molecular Insight
            Pharmaceuticals to assist Nordion in manufacturing BMIPP and in
            carrying out its obligations hereunder;

      (iii) to Molecular Insight Pharmaceuticals' knowledge, there is no action
            or proceeding pending or threatened against Molecular Insight
            Pharmaceuticals before any court, administrative agency or other
            tribunal which might have an adverse material effect on its ability
            to perform its obligations hereunder;

      (iv)  it has the right to grant the license in section 8.1 and right to
            permit Nordion to use the patents, technology and know how provided
            to the extent required to assist Nordion in carrying out its
            obligations under this Agreement;

      (v)   it has not received any notice of adverse claim or infringement of
            any patent, copyright, or misappropriation of trade secrets in
            connection with the use and exploitation of the Precursor, Reference
            Standard or BMIPP;

      (vi)  to Molecular Insight Pharmaceuticals' best information and belief,
            use or sale of Precursor, Reference Standards and BMIPP and the
            data, information, technology and know how used in the Process and
            manufacture of BMIPP contributed by Molecular Insight
            Pharmaceuticals do not infringe any valid third party patent,

<PAGE>

                                       11

            pending published patent application or other intellectual property
            right.

              ARTICLE 10 - NORDION'S REPRESENTATIONS AND WARRANTIES

10.1  Representations and Warranties

      Nordion represents, warrants and covenants that:

      (i)   it has full right and authority to enter into this Agreement;

      (ii)  it is the owner or has the right to use the data, information and
            technology contributed by it with respect to the Background
            Technology and other proprietary technology contributed by Nordion
            during the Agreement;

      (iii) the Background Technology contributed by Nordion does not, to
            Nordion's best information and belief, infringe any patents,
            copyright or other industrial or intellectual property rights of
            third parties;

      (iv)  it has not received any notice of adverse claim of infringement of
            any patent or misappropriation of trade secrets in connection with
            the use and exploitation of the data, information and technology
            used with respect to Background Technology contributed by Nordion;
            and

      (v)   to Nordiont's knowledge, there is no action or proceeding pending or
            threatened against Nordion before any court, administrative agency
            or other tribunal which might have a adverse material effect on
            Nordion's ability to perform its obligations hereunder.

                             ARTICLE 11 - INDEMNITY

11.1  Indemnification by Molecular Insight Pharmaceuticals

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,
      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits ("General
      Claims Against Nordion") arising out of (a) Molecular Insight
      Pharmaceuticals' or a third party's use, handling or shipment of Reference
      Standards, Precursor or BMIPP, (b) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder,
      or (c) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct. Notwithstanding the foregoing, Molecular Insight
      Pharmaceuticals will not be required to indemnify, defend and hold Nordion
      and its Affiliates and their respective directors, officers, employees and
      agents harmless from and against any General Claims Against Nordion to the
      extent that such claims arise out of (i) Nordion's

<PAGE>

                                       12

      breach of any of its obligations, warranties or representations hereunder;
      (ii) Nordion's negligent acts or omissions or willful misconduct; (iii)
      any failure of Nordion to manufacture, handle, store, label, package,
      transport or ship BMIPP in accordance with this Agreement, cGMPs or any
      other applicable laws, rules, regulations or other requirements of any
      applicable governmental entity; or (iv) any failure of Nordion to
      manufacture BMIPP consistent with the Specifications and requirements set
      forth herein or with the applicable sections of Molecular Insight
      Pharmaceuticals' IND in the United States. Notwithstanding anything in
      this Section 11.1, "General Claims Against Nordion" shall not include "IP
      Claims Against Nordion" as described in Section 11.3.

11.2  Indemnification by Nordion

      Nordion agrees to indemnify, defend and hold Molecular Insight
      Pharmaceuticals and its Affiliates and their respective directors,
      officers, employees and agents, harmless from and against any damages,
      claims, liabilities and expenses (including, but not limited to,
      reasonable attorney's fees) resulting from any third party claims or suits
      ("General Claims Against Molecular Insight Pharmaceuticals") arising out
      of (a) Nordion's manufacture, handling, storage, labeling, packaging or
      delivery of the BMIPP; (b) Nordion's breach of any of its obligations,
      warranties or representations hereunder; (c) Nordion's negligent acts or
      omissions or willful misconduct; (d) any failure of the BMIPP to meet the
      Specifications; or (e) any failure of Nordion to manufacture, handle,
      store, label, package, transport or ship BMIPP in accordance with this
      Agreement or cGMPs or any other applicable laws, regulations or other
      requirements of any applicable governmental entity. Notwithstanding the
      foregoing, Nordion will not be required to indemnify, defend and hold
      Molecular Insight Pharmaceuticals and its Affiliates and their respective
      directors, officers, employees and agents harmless from and against any
      General Claims Against Molecular Insight Pharmaceuticals to the extent
      that such claims arise out of (i) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder;
      (ii) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct; (iii) any defect or failure of Reference Standards or
      Precursor to meet applicable specifications or (iv) Molecular Insight
      Pharmaceuticals' or third party's use of BMIPP. Notwithstanding anything
      in this Section 11.2, "General Claims Against Molecular Insight
      Pharmaceuticals" shall not include "IP Claims Against Molecular Insight
      Pharmaceuticals" as described in Section 11.4.

11.3  Intellectual Property Claims Against Nordion

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,

<PAGE>

                                       13

      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorneys' fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Process, method of manufacture, use or sale of the
      Reference Standards, Precursors or BMIPP infringes a United States or
      Canadian patent or any other intellectual property or proprietary right of
      a third party ("IP Claims Against Nordion"). Notwithstanding the
      foregoing, to the extent the Process or method of manufacture is developed
      or contributed by Nordion, Molecular Insight Pharmaceuticals will not be
      required to indemnify, defend or hold harmless Nordion or its Affiliates,
      and their respective directors, officers, employees and agents from and
      against IP Claims Against Nordion.

11.4  Intellectual Property Claims Against Molecular Insight Pharmaceuticals

      Nordion agrees to indemnify, defend and hold harmless Molecular Insight
      Pharmaceuticals and its Affiliates, and their respective directors,
      officers, employees and agents from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Background Technology, the method of manufacture of
      BMIPP or the Process, to the extent developed or contributed by Nordion,
      infringes a United States or Canadian patent or any other intellectual
      property or proprietary right of a third party ("IP Claims Against
      Molecular Insight Pharmaceuticals").

11.5  Infringement

      In the event that any portion of the Background Technology or technology
      developed or contributed by Nordion under this Agreement becomes the
      subject of a claim for a patent, copyright or other industrial or
      intellectual property rights infringement action by a third party, Nordion
      may,

      (i)   if such technology was contributed by Nordion, procure the right to
            continue using the radiolabelling technology within a reasonable
            time not to exceed sixty (60) days; or

      (ii)  modify the Process (to the extent developed or contributed by
            Nordion) to become non-infringing; or

      (iii) if neither (i) nor (ii) are possible, upon written notice to
            Molecular Insight Pharmaceuticals immediately cease its activities
            and/or terminate this Agreement.

      The cost and expense of any opinion of counsel sought by Nordion under
      this section shall be borne by Nordion. Nordion reserves the right to
      control and direct the defense and/or settlement of such claim with legal
      counsel of its choosing; provided, however, that it may not settle such

<PAGE>

                                       14

      claims without the prior written consent of Molecular Insight
      Pharmaceuticals, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Molecular Insight
      Pharmaceuticals shall be required if such settlement includes a full
      release of Molecular Insight Pharmaceuticals.

      In the event that any portion of the Process that was developed or
      contributed by Molecular Insight Pharmaceuticals becomes the subject of a
      claim for a patent, copyright or other industrial or intellectual property
      rights infringement action by a third party, Molecular Insight
      Pharmaceuticals may, (i) within a reasonable time not to exceed sixty (60)
      days procure the right to continue using the Process or technology, (ii)
      modify the Process, to the extent contributed by Molecular Insight
      Pharmaceuticals, to become non-infringing or (iii) if neither (i) nor (ii)
      are reasonably possible, Molecular Insight Pharmaceuticals may terminate
      this Agreement upon written notification to Nordion. Molecular Insight
      Pharmaceuticals reserves the right to control an direct the defense and/or
      settlement of such claims with legal counsel of its choosing; provided,
      however, that it may not settle such claims without the prior written
      consent of Nordion, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Nordion shall be required if
      such settlement includes a full release of Nordion.

11.6  Indemnification Procedures

      A party (the "indemnitee") which intends to claim indemnification under
      this Article 11 shall promptly notify the other party (the "Indemnitor")
      in writing of any action, claim or other matter in respect of which the
      Indemnitee or any of its directors, officers, employees or agents intend
      to claim such indemnification; provided, however, the failure to provide
      such notice within a reasonable period of time shall not relieve the
      Indemnitor of any of its obligations hereunder except to the extent the
      Indemnitor is materially prejudiced by such failure. The Indemnitor shall
      be entitled to control the defense of and/or settle any such action, claim
      or other matter. The Indemnitee agrees to the complete control of such
      defense or settlement by the Indemnitor, provided, however, any settlement
      of such claims shall require the Indemnitee's prior written consent unless
      such settlement includes a full release of the Indemnitee, in which case
      no consent shall be required. The Indemnitee and its directors, officers,
      employees and agents shall co-operate fully with the Indemnitor and its
      legal representatives in the investigation and defence of any action,
      claim or other matter covered by this indemnification. The Indemnitee
      shall have the right, but not the obligation, to be represented by counsel
      of its own selection and at its own expense.

<PAGE>

                                       15

                       ARTICLE 12 - PATENTS AND TECHNOLOGY

12.1  Ownership of Work Performed

      The portion of the Process as developed or contributed by Molecular
      Insight Pharmaceuticals shall be the sole and exclusive property of
      Molecular Insight Pharmaceuticals. Except to the extent the Process is
      developed or contributed by Molecular Insight Pharmaceuticals, Molecular
      Insight Pharmaceuticals agrees and acknowledges that any and all ideas,
      technology, method, data, information, inventions, improvements,
      derivative works and works of authorship conceived, written, created or
      first reduced to practice in the performance of the development of the
      Process, Background Technology and improvements to the Background
      Technology during the term of this Agreement, shall be the sole and
      exclusive property of Nordion.

                         ARTICLE 13 - REGULATORY MATTERS

13.1  Regulatory Status

      Upon Nordion's reasonable request, Molecular Insight Pharmaceuticals shall
      provide updates to Nordion on (i) the progress of Clinical Trials related
      to BMIPP, and (ii) submissions to the FDA and other jurisdictions and
      regulatory agencies for marketing authorization with respect to BMIPP.

13.2  Molecular Insight Pharmaceuticals Responsibilities

      It shall be the responsibility of Molecular Insight Pharmaceuticals or its
      designee to file, obtain and maintain an IND, registrations, listings,
      authorizations and approvals as the FDA or any other applicable
      governmental entity may require to enable use of BMIPP in Clinical Trials
      in the United States. Nordion shall provide directly to Molecular Insight
      Pharmaceuticals, or at Nordion's discretion for the purpose of protection
      of its proprietary technology with respect to the manufacture of the
      Isotope, directly to the regulatory authority all required information in
      its possession necessary to assist Molecular Insight Pharmaceuticals in
      filing, obtaining and maintaining all licenses, registrations, listings,
      authorizations and approvals of any governmental entities necessary for
      the use of BMIPP in support of Molecular Insight Pharmaceuticals' BMIPP
      NDA submission.

13.3  Nordion Responsibilities

      Nordion shall be responsible for obtaining and maintaining all necessary
      Facility licenses, registrations, authorizations and approvals which are
      necessary to develop, manufacture, handle, store, label, package,

<PAGE>

                                       16

      transport and ship BMIPP under cGMP conditions and other regulatory
      requirements including, but not limited to, the use and handling of
      radioactive materials.

      At Nordion's expense, Nordion shall update its existing 1-123 bulk
      chemical or facility description Drug Master File ("DMF") with the FDA as
      may be required for Molecular Insight Pharmaceuticals' NDA for BMIPP in
      accordance with Schedule A. Nordion hereby grants Molecular Insight
      Pharmaceuticals a right of reference to such DMF, and upon request shall
      provide a letter of access to the DMF allowing regulatory review of the
      DMF by the FDA in conjunction with Molecular Insight Pharmaceuticals'
      BMIPP submissions. At Nordion's expense, Nordion shall apply for and seek
      a DMF for BMIPP in accordance with Schedule A.

13.4  Government Inspections, Compliance Review and Inquiries

      Upon request of any governmental entity or any third party entity
      authorized by a governmental entity, such entity shall, for the purpose of
      regulatory review, have access to observe and inspect the (i) Facility,
      (ii) procedures used for the storage of Reference Standards and Precursor,
      and (iii) manufacturing, testing, storage and shipping of BMIPP, including
      Process development operations, and auditing the Facility for compliance
      with cGMP and/or other applicable regulatory standards. Nordion shall give
      Molecular Insight Pharmaceuticals prompt written notice of any upcoming
      inspections or audits by a governmental entity of the Facility or any of
      the foregoing and shall allow Molecular Insight Pharmaceuticals to
      participate in such audits by being present at any FDA close out meeting
      and shall provide Molecular Insight Pharmaceuticals with a written summary
      of such inspection or audit following completion thereof. Nordion agrees
      to use commercially reasonable efforts to promptly rectify or resolve any
      deficiencies noted by a government entity in a report or correspondence
      issued to Nordion.

13.5  Access to the Facility

      Molecular Insight Pharmaceuticals shall have reasonable access to the
      Facility at least once per calendar quarter during the Development Phase
      for the purpose of observing Process development relating to BMIPP.
      Molecular Insight Pharmaceuticals shall provide to Nordion at least five
      (5) business days prior written notice of requested access to the Facility
      for the purpose of this Section. All such information disclosed to
      Molecular Insight Pharmaceuticals or its employees or agents, shall be
      deemed to be Nordion's Confidential Information as such term is defined in
      Section 14.1 of this Agreement.

13.6  Recalls

<PAGE>

                                       17

      Molecular Insight Pharmaceuticals shall notify Nordion promptly if BMIPP
      is the subject of a recall or correction (a "Recall"), and Molecular
      Insight Pharmaceuticals and/or its designee shall have sole responsibility
      for the handling and disposition of such Recall. Molecular Insight
      Pharmaceuticals and/or its designee shall bear the costs of any Recall of
      BMIPP unless and to the extent such Recall shall have been the result of
      Nordion's or its employees acts of omissions or any product defects for
      which Nordion is responsible in which case Nordion shall to such extent be
      responsible for all of Molecular Insight Pharmaceuticals' out-of-pocket
      costs incurred for:

      (i)   notification of recall to Nordion and third parties;

      (ii)  return shipment of any defective BMIPP to Nordion; and

      (iii) replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault is due to Nordion and/or to its agent, the
      parties will select a mutually agreeable outside consulting firm which
      will be instructed to review the applicable information and data and to
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will pay the fees of such consulting firm. If the
      consulting firm dissents from Molecular Insight Pharmaceuticals'
      determination Nordion will not have the obligations set forth herein with
      respect to the Recall and Molecular Insight Pharmaceuticals will pay the
      fees of such consulting firm. Molecular Insight Pharmaceuticals and/or its
      designee shall maintain records of all sales, shipping records of BMIPP
      and customers in sufficient detail to adequately administer a Recall for
      the period of time as required by applicable regulation.

13.7  New Regulatory Requirements

      Each party shall promptly notify the other of new regulatory requirements
      of which it becomes aware which are relevant to the manufacture of BMIPP
      under this Agreement and which are required by the FDA and other
      applicable governmental entities and the parties shall confer with each
      other with respect to the best means to implement and comply with such
      requirements.

13.8  Records

      Nordion shall maintain all records necessary to evidence compliance with
      (i) all applicable laws, regulations and other requirements of applicable
      governmental entities in the United States and Canada relating to the
      supply and manufacture of BMIPP; (ii) the Specifications; and (iii)
      obligations under this Agreement. All such records shall be maintained by

<PAGE>

                                       18

      Nordion for at least two (2) years after termination or expiration of this
      Agreement. Nordion shall provide to Molecular Insight Pharmaceuticals
      reasonable access to such records upon request. Prior to destruction of
      any record after such time, Nordion shall give written notice to Molecular
      Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall have the
      right to request that Nordion maintain such records in an off site storage
      facility for such longer periods as Molecular Insight Pharmaceuticals
      requests, provided that Molecular Insight Pharmaceuticals pays all costs
      associated with such off site storage.

                          ARTICLE 14 - CONFIDENTIALITY

14.1  Confidentiality and Exceptions

      During the term of this Agreement and for a period of ten (10) years
      thereafter, each party hereto shall maintain in confidence the content of
      the transactions contemplated herein, all technology including Background
      Technology and improvements thereto, Nordion proprietary technology,
      Molecular Insight Pharmaceuticals proprietary technology, trade secrets,
      know-how, data, processes, methods, techniques, formulas and test data
      (collectively "Confidential Information") and other information disclosed
      to such party by the other party which is identified as "Confidential
      information" by the disclosing party. This obligation of confidentiality
      shall not apply to the extent that it can be established by the party in
      receipt of such information, that the information:

      (i)   was already known to the receiving party at the time of disclosure;

      (ii)  was generally available to the public or otherwise part of the
            public domain at the time of its disclosure;

      (iii) became generally available to the public or otherwise part of the
            public domain after its disclosure to the receiving party through no
            act or omission of the receiving party;

      (iv)  was disclosed to the receiving party by a third party who was not
            known or ought to be known to the receiving party to have
            obligations restricting disclosure of such information; or

      (v)   was independently developed by the receiving party without any use
            of Confidential Information of the disclosing party.

      Each party agrees that it will take the same steps to protect the
      confidentiality of the other party's Confidential Information as it takes
      to protect its own proprietary and confidential information, which shall
      in no event be less than commercially reasonable steps. Each party, and
      its employees and agents shall protect and keep confidential and shall not
      use, publish or otherwise disclose to any third party, except as permitted
      by this Agreement, as necessary to perform its obligations hereunder, or

<PAGE>

                                       19

      with the other party's written consent, the other party's Confidential
      Information.

      It is agreed that disclosure of data, information or technology by
      Molecular Insight Pharmaceuticals or Nordion to the other under this
      Agreement shall not constitute any grant, option or license under any
      patent, technology or other rights, held by Molecular Insight
      Pharmaceuticals or Nordion. Any use of the data, information and
      technology provided by Molecular Insight Pharmaceuticals to Nordion which
      relates to Precursor, Reference Standards or radiolabelling of Precursor
      shall be for the limited purpose of assisting Nordion in carrying out its
      obligations under this Agreement. All data, information, or technology
      supplied by one party to the other to assist in carrying out the
      obligations hereunder shall remain the property of such party and shall be
      returned to the other party upon termination of this Agreement.

                     ARTICLE 15 - DISCLOSURE OF INFORMATION

15.1  Authorized Disclosure

      Notwithstanding section 14.1 each party may disclose Confidential
      Information to the extent such disclosure is reasonably necessary for
      prosecuting or defending litigation and/or complying with applicable
      government laws or regulations, provided that if a party is required by
      law or regulation to make any such disclosure of the other party's
      Confidential Information it will give reasonable notice to the other party
      of such disclosure requirement.

                        ARTICLE 16 - TERM AND TERMINATION

16.1  Initial Term

      The term of this agreement shall commence upon the Effective Date and,
      unless terminated earlier pursuant to this agreement, or extended upon
      mutual agreement of the parties, shall expire on December 31, 2005.

16.2  Termination Without Cause

      Molecular Insight Pharmaceuticals may terminate this Agreement without
      cause or penalty upon thirty- (30) day's prior written notice to Nordion.
      Upon such termination, Nordion shall be entitled to retain all amounts
      paid by Molecular Insight Pharmaceuticals and Molecular Insight
      Pharmaceuticals shall pay to Nordion any amounts due and/or earned but not
      yet paid.
<PAGE>

                                       20

16.3  Termination for Breach

      This Agreement may be terminated by either party in the event of the
      material breach by the other party of the terms and conditions hereof;
      provided, however, the other party shall first give to the breaching party
      written notice of the proposed termination of this Agreement (a "Breach
      Notice"), specifying the grounds therefor. Upon receipt of such Breach
      Notice, the breaching party shall have such time as necessary, but in any
      event not more than thirty (30) days to cure such breach. Notwithstanding
      the foregoing, if the breaching party does not cure such breach within
      such cure period, the other party may terminate the Agreement without
      prejudice to any other rights or remedies which may be available to the
      non-breaching party.

16.4  Bankruptcy

      This Agreement may be terminated by a party in the event the other party
      files a petition in bankruptcy, is adjudicated a bankrupt, makes an
      assignment for the benefit of its creditors, or otherwise seeks relief
      under or pursuant to any bankruptcy, insolvency or reorganization statute
      or proceeding, or if a petition in bankruptcy is filed against it which is
      not dismissed within ninety (90) days or proceedings are taken to
      liquidate the assets of such party.

                             ARTICLE 17 - SURVIVAL

17.1  Consequences or Termination or Expiration

      Upon expiration or termination of this Agreement, the obligations of the
      parties under Articles 9, 10, 11, 12, 14, 15, 19 and 24 shall survive such
      expiration or termination in accordance with its terms.

                               ARTICLE 18-NOTICES

18.1  Any notice to be sent to a party hereunder shall be forwarded to:

      Nordion at:     MDS Nordion
                      447 March Road
                      Ottawa, ON
                      K2K 1X8
      Attention:      Senior Vice President, Nuclear Medicine
                      Fax:

      Molecular Insight Pharmaceuticals at:

<PAGE>

                                       21

                      Molecular Insight Pharmaceuticals, Inc.
                      160 Second Street
                      Cambridge, MA
      Attention:      Chief Operating Officer
                      Fax: 617-492-5664

      Any notice required or authorized to be given by a party to the other in
      accordance with the provisions of this Agreement shall, unless otherwise
      specifically stipulated, be in writing and delivered personally, by a
      nationally recognized overnight courier, or if by electronic facsimile
      confirmed by certified or registered mail. Notice shall be deemed
      delivered upon receipt.

                         ARTICLE 19 - LIMITED LIABILITY

19.1  Disclaimer

      In no event shall either party be liable to the other party for indirect,
      punitive, contingent, incidental, special or consequential damages.

19.2  Limitation of Product Warranty

      MOLECULAR INSIGHT PHARMACEUTICALS ACKNOWLEDGES THAT NORDION IS
      MANUFACTURING AND SUPPLYING BMIPP TO MEET SPECIFICATIONS. EXCEPT AS
      EXPRESSLY SET OUT IN THIS AGREEMENT, NORDION HEREBY DISCLAIMS ALL OTHER
      WARRANTIES OR CONDITIONS, WHETHER EXPRESS OR IMPLIED, STATUTORY OR
      OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OR
      CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                   ARTICLE 20 - ASSIGNMENT AND SUBCONTRACTING

20.1  No Assignment

      This Agreement shall enure to the benefit of and shall be binding upon the
      heirs, executors, administrators, successors and permitted assigns of the
      parties. Neither Nordion nor Molecular Insight Pharmaceuticals shall
      assign this Agreement or any portion of this Agreement without the written
      approval of the other party, which approval shall not be unreasonably
      withheld; provided, however, that Molecular Insight Pharmaceuticals may
      assign this Agreement without Nordion's consent in connection with the
      sale of all or substantially all of its stock or assets to a third party
      or in connection with a merger, consolidation or similar transaction.

                             ARTICLE 21 - COMPLIANCE

21.1  Compliance with Laws

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       22

      This Agreement and Nordion's and Molecular Insight Pharmaceuticals'
      obligations hereunder shall be carried out in compliance with all
      applicable laws, by-laws, rules, regulations and orders of all applicable
      Federal, State, Provincial and Municipal governments.

                             ARTICLE 22 - NON-WAIVER

22.1  Non-Waiver of Rights

      Failure by either party to enforce at any time any of the provisions of
      this Agreement shall not be constructed as a waiver of its rights
      hereunder. Any waiver of a breach of any provision hereof shall not be
      effective unless in writing and shall not affect either party's rights in
      the event of any additional breach.

22.2  Force Majeure

      Neither party shall be liable to the other for failure to perform or delay
      in performing its obligations under this Agreement by virtue of the
      occurrence of an event of Force Majeure. In the event of Force Majeure,
      the party affected shall promptly notify the other and shall exert
      commercially reasonable efforts to eliminate, cure or overcome such event
      and to resume performance of its obligations. In the event such Force
      Majeure affecting either party continues for more than thirty (30) days
      the party not subject of the Force Majeure may terminate this Agreement.
      "Force Majeure" shall mean an occurrence which prevents, delays or
      interferes with the performance by a party of any of its obligations
      hereunder if such event occurs by reason of any act of God, flood, power
      failure, fire, explosion, casualty or accident, or war, revolution, civil
      commotion, acts of public enemies, blockage or embargo, or any law, order
      or proclamation of any government, failure of suppliers or usually
      supplier to provide materials, equipment or machinery, interruption of or
      delay in transportation, strike or labor disruption.

                             ARTICLE 23 - INSURANCE

23.1  Product Liability Insurance

      During the term of this Agreement and for a period of one (1) year
      thereafter Molecular Insight Pharmaceuticals at its own expense shall
      provide and maintain a products liability insurance policy issued by a
      reputable insurance company with respect to BMIPP. Such policy shall add
      Nordion as an additional insured and shall have a limit of liability of
      not less than three million United States dollars ($3,000,000 US) per
      occurrence and in the aggregate. Molecular Insight Pharmaceuticals shall

<PAGE>

                                       23

      be solely responsible for any deductible or retention associated with this
      policy and such deductible or retention amounts shall not affect Nordion's
      interests. The policy shall contain a cross liability clause and shall
      provide for severability of interest such that breach of a policy
      condition committed by any one insured shall not adversely affect the
      rights of the other insured. Nordion shall be provided thirty (30) days'
      prior written notice of any material change to the policy and such change
      shall be subject to Nordion's prior written consent, which consent shall
      not be unreasonably withheld. Nothing contained in this Section shall be
      deemed to limit in any way the indemnification provisions contained in
      this Agreement.

                            ARTICLE 24 - PUBLICATION

24.1  Publicity

      The parties agree that, except as may otherwise be required by applicable
      laws, regulations, rules or orders or in connection with obtaining
      regulatory approvals for BMIPP, no information concerning this Agreement
      and the transactions contemplated herein shall be made public by either
      party without the prior written consent of the other, which consent shall
      not be unreasonably withheld or delayed. In the event either party decides
      to issue a press release announcing the execution of this Agreement, it
      shall not do so without the prior written approval of the other party.

      A copy of any proposed press release shall be provided to the other party
      for approval at least three (3) business days prior to any proposed
      release.

      In the event that this Agreement or any portion of its contents is
      required to be disclosed by Molecular Insight Pharmaceuticals or Nordion
      pursuant to Security Exchange Commission rules or regulations or other
      federal or state authorities, Molecular Insight Pharmaceuticals or
      Nordion, as the case may be, shall provide reasonable notice to the other
      prior to any such disclosure in order that, to the extent possible while
      enabling the party to comply with the applicable laws, rules and
      regulations, the content so disclosed does not include information which
      may reasonably be considered by the other as confidential, proprietary
      and/or commercially sensitive information.

                         ARTICLE 25 - DISPUTE RESOLUTION

25.1  Dispute Resolution

      Except as otherwise set out, in the event that at any time during the term
      of this Agreement, a disagreement, dispute, controversy or claim should
      arise relating to the (i) interpretation of or performance under this

<PAGE>

                                       24

      Agreement or the attribution of liability or breach thereof; or (ii)
      scientific or technical issues in connection with Nordion or Molecular
      Insight Pharmaceuticals' performance under this Agreement, the parties
      will attempt, in good faith, to resolve their differences for a period of
      thirty (30) days following written notice from one party to the other
      specifying such dispute(s). In the event the parties are unable to work
      out a resolution of the issue during such 30-day period, either party
      shall be free to take any action and seek any remedy it may have at law or
      in equity including specific performance and injunctive relief.

                       ARTICLE 26 - INDEPENDENT CONTRACTOR

26.1  No Joint Venture

      The parties agree that with respect to the transactions contemplated
      herein that they shall both be acting as independent contractors and
      nothing herein shall constitute the parties as entering into a joint
      venture or partnership, nor shall anything herein constitute either party
      as an agent of the other for any purpose whatsoever.

                            ARTICLE 27 - SEVERABILITY

27.1  Invalid Provisions

      If any provision or term of this Agreement is found unenforceable under
      any of the laws or regulations applicable thereto, all other conditions
      and provisions of this Agreement shall nevertheless remain in full force
      and effect. Upon such determination that any term or other provision is
      invalid, illegal or incapable of being enforced, the parties hereto shall
      negotiate in good faith to modify this Agreement to effect the original
      intent of the parties as closely as possible in a mutually acceptable
      manner, in order that the transaction contemplated hereby be consummated
      as originally contemplated to the greatest extent possible.

                             ARTICLE 28 - AGREEMENT

28.1  Entire Agreement

      This Agreement, including the Schedules hereto which are incorporated
      herein, constitute the entire agreement of the parties with respect to the
      subject matter hereof and supersedes all proposals, oral or written, and
      all negotiations, conversations, or discussions. This Agreement may not be
      modified, amended, rescinded, canceled or waived, in whole or in part,
      except by written amendment signed by both parties hereto.

<PAGE>

                                       25

                                ARTICLE 29 - LAW

30.1  Applicable Law

      This Agreement shall be governed and construed in accordance with the laws
      of the Province of Ontario, Canada, without reference to its principles on
      conflict of laws. The application of the United Nations Convention for the
      International Sale of Goods is expressly excluded.

<PAGE>

                                       26

      IN WITNESS WHEREOF the parties hereto have executed this agreement as of
the date first above written.

MDS Nordion,                             Molecular Insight Pharmaceuticals, Inc.
a division of MDS (Canada) Inc.

By: /s/ Gerry Vantellingen              By: /s/ John W. Babich
    ---------------------------            ------------------------

#63441 v1 - Agreement/Molecular Insight/Final
<PAGE>

                                   SCHEDULE A

                                  Scope of Work

<TABLE>
<CAPTION>
                                                                                               Commence
                                         ACTIVITY                                Duration   -------------
                                         --------                                --------    Y weeks from
                                                                                  X weeks   Effective Date
                                                                                 --------   --------------
<S>                                                                              <C>        <C>
1. Activity 1 - Technology Transfer

   a) Review Customer Supplied Documentation                                         2             1
   b) Write, review and approve Preliminary Safety Analysis Report(PSAR)             3             2
   c) Experimental Design for Scale-Up                                               2             2
   d) Scale-Up to 1 Ci (up to 10 runs maximum)
      i)   Show reproducibility of procedure                                         5             5
      ii)  Increase yield to 80% after quenching and isolation
           (commercially reasonable best efforts)

      iii) Verify autoclavability of formulation. Establish excipient
               ranges

   e) Scale up to 4 Ci (up to 5 runs)                                                3            10
   f) Document experiments and archive data (HPLC traces,                            3            13
      logbooks, etc.)
   Milestone 1 : Complete Technology Transfer                                        0            16

2. Activity 2- Reformulation and Purification

   a) Develop HPLC Separation Method                                                 6             4
   b) Develop Automation: sample transfer and collection                             4             4
   c) Develop compatibility of HPLC collected fraction with                          2             4
      Formulation. Establish excipients
   d) IQ/OQ and validate autoclave.                                                  5             4
   e) IQ/OQ/PQ for HPLC and equipment.                                               6            16
   f)  Draft Master Batch Record for Molecular Insight approval.                     2            19
   Milestone 2: Complete Reformulation and Purification                              0            21

3. Activity 3- Develop Dispensing Equipment

   a) Develop dispensing setup for 30 vial capability                               10             9
      - IQ/OQ/PQ Dispensing
      - Seal and crimp

   b) Develop container/ closure system                                              8            11
      - Complete closure test and integrity
      - Complete recoverability of dose from Container Test
   c) Establish Class 100 conditions for dispensing box at vial                      1            19
      opening.
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   d) IQ/OQ/PQ Shielded boxes (SB)                                                   2            20
      - calibrate gauges
      - establish airborne I-123 detection system
   e) IQ/OQ/PQ Laminar Air Flow (LAF) Assembling Area.   .                           2            20
   f) Initiate Environmental Monitoring in LAF, SB and                               3            20
      Controlled Access Room,
   Milestone 3: Complete Dispensing Equipment Development                            0            22

4. Activity 4- Develop Q.C. Test Methods

   a) HPLC Method for Final Product.                                                 4            22
      - verify                      1) BMIPP
                                    2) UDCA
                                    3) Any other identified
                                 impurities as per specifications in
                                 Schedule F.
      -   establish 1) Radiochemical Purity
                     2) Chemical purity - Quantitative method
      Note: this is a method transferred from Molecular Insight
      -   Write and approve Standard Test Method (STM)
   b) IQ/OQ/PQ Dose Calibrator                                                       2            26
       Write and Approve STM
   c) Gamma Spectroscopy                                                             1            26
      -   Calibration Protocol
      -   NIST traceability
      -   159 keV Identification (ID) for I-123
      -   Write.and approve STM
   d) Endotoxin Test (USP)                                                           1            28
      -   Dilution to overcome Inhibition/Enhancement
      -   Maximum valid dilution
      -   Qualification of test method
      -   Write and approve STM
   e) Sterility Test (USP)                                                           1            28
      -   Establish sampling size
      -   Write and approve STM
   f) Product Release Form (PRF)                                                     1            29
      -   Identify all documents necessary for batch release
   Milestone 4: Complete QC Test Methods Development                                 0            30

5. Activity 5- Validation of New Process

   a) Write and approve Master Validation Plan                                       8             4
      -    Equipment: Analytical and Process
      -    Analytical Methods
      -    Process
      -    Final Product Stability
   b) Method Transfer Validation                                                     6            30
      -    Analytical Methods
      -    References Standards (shelf-life; ID)
      -    Precursor (ID; shelf-life)
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Validation Protocols                                                           2            36
   d) Six Process Runs to fine tune process                                          6            28
   e) Train Operators                                                                6            28
      - 3 Production technicians

      - 3 QC/QA

      - 2 Packaging
   Milestone 5: Complete Validation of New Process                                                34

6. Activity 6- Perform GMP Equivalency Run (Validation Runs)                         3            34

   a) Perform three runs (1 Ci of I-123)                                             3            37
   b) Compile all data for validation files                                          0            40
   Milestone 6: Complete Validation Runs

7. Activity 7- Prepare Development Report

   a) Document all experimentation                                                   6            31
   b) Archive all data/logbooks                                                      6            31
   c) Write and approve Development Report                                           6            39
      - Process Description and Development

      - Master Formula

      - Impurities profiles (standards to be provided by

        Molecular Insight)
      - Excipient Ranges

      - Final Product Specifications

      - Scale-Up rationale

      - Equivalence to previous formulation ( to be done in
        conjunction with Molecular Insight at their cost)

      - Qualification of Reference Standards to be done by
        Molecular Insight

      - Precursor made under cGMPs to be provided by
        Molecular Insight

      - Analytical Method and Validation to be done by
        Molecular Insight

      - Bioburden Profiles for Raw Material

      - Environmental data - house isolates

      - Molecular insight to provide stability indicating
        methods for final product

      - Define Utilities

      - Cleaning Protocol
   Milestone 7: Submit Development Report                                                         45

8. Activity 8- DMF / CMC Package

   a) Provide SOPs/STMs for CMC section of NDA                                       3            37
   b) Provide flowcharts                                                             3            37
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Establish Review and Approval responsibility for                               3            37
      documents
   d) Establish Recall procedure                                                     3            37
   e) Establish responsibilities of                                                  3            37
      1) Deviations

      2) Change Control

      3) Product Release

      4) Failure Investigation

      5) Out-of-Spec Investigation

      6) Draft required procedures

   Milestone 8: DMF/CMC Package Complete                                                          40

9. Activity 9- Prepare for PAI

   a) audit for cGMP compliance (with customer)                                      3            40

   b) Review findings and establish action plan                                      3            40

   c) Review costs of ongoing and enhanced compliance (to be                         3            40
      billed to Molecular Insight as required)

      NOTE: PAI readiness will
      require additional staffing and/or consultants that will be charged
      to Molecular Insight.
   Milestone 9: Ready for PAI                                                                     43
</TABLE>

   Pcdocs 62635
<PAGE>

                                   SCHEDULE B

              FACILITY RESOURCES FOR CONTRACT MANUFACTURE OF BMIPP

THE FOLLOWING EQUIPMENT IS USED TO MANUFACTURE BMIPP:

-     Laminar Flow Hood for reagent and equipment preparation

-     Three Lead shielded glove boxed with HEPA filtration and Nuclear
      Ventilation

      -     Box 1 reaction, separation, formulation box containing
            semi-preparative automated HPLC for drug substance isolation

      -     Box 2 has the function to act as a dispensing area. The
            dispensing environment is class 100

      -     Box 3 is the terminal sterilization box containing an
            autoclave and a remote handling ball and tong manipulator

-     Specialized shielding assemblies are used for the safe transport of
      formulated unit dose radiopharmaceuticals

-     Fume hood with nuclear ventilation for QC analysis

-     HPLC equipment for QC analysis

-     Dose calibrator

-     Particle check station

-     Gamma Spectroscopy system

-     Refrigerator

SOME GENERAL FEATURES OF THE MANUFACTURING AREA AND SUPPORT SERVICES ARE:

-     The room is environmentally and radiation monitored

-     There are waste handling systems in place to deal with chemical waste
      streams as well as solid and liquid radioactive wastes

-     The entire manufacturing environment is cGMP regulated

-     Qualified and trained staff with experience in diagnostic
      radiopharmaceutical manufacture are employed

-     The entire manufacturing facility is supported by a calibration department

-     A fully outfitted microbiology lab is available for microbiological and
      environmental tests (Most importantly LAL tests for pyrogenicity)

-     There is an attached microbiology clean room used for sterility tests and
      filtration.

-     This clean room contains a class 100 glove box.

NOTE: EQUIPMENT OTHER THAN THAT LISTED ABOVE (SUCH AS HOT CELLS ETC.) MAY BE
USED DURING DEVELOPMENT

<PAGE>

                                   SCHEDULE C

                         BMIPP PRECURSOR SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>

                                   SCHEDULE D

                       REFERENCE STANDARDS SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>

                               SPECIFICATION SHEET

TCI America, 9211 N Harborgate St,
Portland, OR 97203                 Version Date 3/7/02      Form No. :SS. 057.02

Material            BMIPP (INACTIVE COMPONENT/PRECURSOR)         Code No.: Z3398

Formula: C(22)H(35)IO(2)       Molecular Wt.: 458.42        CAS No.: 116754-87-1

Synonym(s):  15-(p-Iodophenyl)-
3-methylpentadecanoic Acid                     Storage Conditions:<or=4C(degree)

<TABLE>
<CAPTION>
Frequency             Test                                 Acceptance Criteria                        Test Procedure
------------------    ----------------------------------   ---------------------------------------    -----------------------
<S>                   <C>                                  <C>                                        <C>
0,3,6,9, 12,          Appearance                           Colorless or white crystals or powder      SLT QC 339
18,24,36,
48, 60mo

0-60 months           Identification              FTIR     Identical to reference standard            SLT QC 327

After manufacture                                 UV-VIS   Identical to reference standard            SLT QC 371

0 - 60 months                                     HPLC     Retention time corresponds with that of    SLT QC 358
                                                           the reference standard within +/- 3%

0-60 months           Purity Assay (HPLC)                  > or = 95%                                 SLT QC 358

After manufacture     Purity, Melting point                51-56(degree)C                             SLT QC 322

After manufacture     Purity, Water analysis (KF)          Report results                             SLT QC 329

0 - 60 months         Impurities, HPLC Related             < or = 2.0 % any single species            SLT QC 358

0 - 60 months         Methyl 15-(p-Iodophenyl)-3           < or = 0.1%                                SLT QC 358
                      Methylpentadecanoate

After manufacture     Heavy metals                         < or = 20 ppm                              SLT QC 332 (Method II)

After manufacture     Residual Solvents

                                   Hexane                  < or = 290 ppm                             SLT QC 340

                                   Methanol                < or = 3000 ppm                            SLT QC 340

                                   Ethyl Acetate           < or = 5000 ppm                            SLT QC 340

                                   Ethanol                 < or = 5000 ppm                            SLT QC 340

                                   Isopropanol             < or = 5000 ppm                            SLT QC 340
After manufacture     Organic Volatile Impurities

                                   Methylene Chloride      < or = 500 ppm                             SLT QC 340
</TABLE>

<PAGE>

                                   SCHEDULE E

                              BMIPP SPECIFICATIONS
<PAGE>

SPECIFICATION SHEET                                                 Page 1 of 1

                        DRUG PRODUCT SPECIFICATION SHEET

<TABLE>
<S>                                                  <C>                <C>
Molecular Insight, 160 Second ST, Cambridge, MA      Version Date       (ACTIVE COMPONENT)
02142                                                 4/13/04
</TABLE>

Material                          [(123)I]-BMIPP              CODE NO.: MIP 1000

Formula: C(22)H(35)IO(2)           Molecular Wt.: 454.42    CAS No.: 116754-87-1

Synonym(s):   [(123)I]-15-(p-Iodophenyl)-3-methylpentadecanoic Acid

<TABLE>
<CAPTION>
            TEST                  ACCEPTANCE CRITERIA          TEST METHOD                TESTING SCHEDULE
<S>                        <C>                                 <C>                        <C>
Appearance                     Clear, Colorless Solution       Visual observation         Test Completed prior
                                                               STM 12                     to release of drug
Radionuclide Identity      Gamma-Photon emission at 159 +/-    Gamma ray Spectroscopy,    Test Completed prior
                            5 keV                              STM 23
                                                                                          to release of drug
Radionuclide Impurity      <or= 2.5% I-125 at TOC              Gamma ray Spectroscopy,    Confirmation Test of
                           <or= 110 (mu)Ci/mL I-125 at TOC     STM 21                     component Nal, After
                                                                                          decay of I-123, 2
                                                                                          weeks after release
Radioactivity                     3.6 to 4.4 mCi/mL            Dose Calibrator            Test Completed prior
Concentration                                                  STM 27                     to release of drug
Radiochemical Identity*       R(r) value between 0.30 to       Normal phase TLC           Test Completed prior
                              0.50
                                                               STM 16                     to release of drug
Radiochemical Purity            >95% as I-123-BMIPP            Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Chemical Concentration            0.36 to 0.44 mg/ml           Reverse phase HPLC         Test Completed prior
                                                               UV-VIS detector            to release of drug
                                                               STM 17
Radiochemical Impurity         <or= 5% as free I-123           Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Radiometric Assay for       4.5 to 5.5 mCi per (1.25 mL)       Dose Calibrator            Test Completed prior
unit dose vial              at TOC
Osmolarity                                                     STM 11                     to release of drug
                                Ratio to Saline 0.8 to         Osmometer, compare with    Test Completed prior
                                  1.0                          normal saline
                                                               STM 18                     to release of drug

pH                                 Range 8.2 to 9.2            pH paper                   Test Completed prior
                                                               STM 19                     to release of drug
Bacterial Endotoxin        <or=4.0 EU/ml                       Limulus Amebocyte Lysate
                                                               test on diluted drug
                                                               product                    Test Completed prior
                                                               STM 14                     to release of drug

Sterility                  No turbidity or growth              2 week incubation in       Test initiated
                                                               Fluid Thioglycollate       within 24 hours of release
                                                               Medium &
                                                               Trypticase Soy Broth
                                                               STM 13
Package Inspection         No damage                           Visual                     Test Completed prior
                                                               STM 15                     to release of drug
</TABLE>

Note: All STM numbers will be changed to equivalent MDS Nordion document
numbers.

* This TLC test may be replaced by HPLC.

TOC = Time of Calibration; 1500 h PT, one day after manufacture

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                PRICE SCHEDULE F

1.    FACILITY ESTABLISHMENT FEE:

      This is a one-time fee for the establishment of the facility described in
      Schedule B.

      PRICE: $[*******] US

      Note: Fee is payable upon signing of the Agreement

2.    MILESTONES PAYMENTS:

<TABLE>
<CAPTION>
   MILESTONE                   DESCRIPTION                  PRICE US$
   ---------                   -----------                  ---------
<S>                  <C>                                    <C>
Milestones 1 & 2     Technology Transfer &                  $[*******].
                     Reformulation and Purification

Milestone 3          Dispensing Equipment                   $[*******].

Milestone 4          QC Test Methods                        $[******].

Milestone 5          Validation of New Process              $[*******].

Milestone 6          GMP Validation Runs                    $[******].

Milestone 7          Development Report                     $[******].

Milestone 8          DMF/CMC Package for                    $[******].
                     BMIPP

Milestone 9          Prepare for PAI                       Not included at this
                                                     time - estimated $[******].
</TABLE>

      Notes - [***] of each Milestone payment is due upon signing of the
      Agreement, [***] when the specific Milestone is commenced and the
      remainder of each Milestone Payment is due upon completion of the
      Milestone.

3.    BATCHES FOR PHASE III CLINICAL SUPPLY:

      Price: US$ [******]. per Batch

      Notes - a)   Batch runs are ~30 doses of BMIPP of which 20 are shippable

              b)   Payment is due within 30 days of the date appearing on
                   Nordion's invoice.

 Pcdocs62680

<PAGE>

                           447 March Road               Tel: +1 613 592 2790
                           Ottawa, ON K2K 1X8           Fax: +1 613 592 6937
                           Canada                       www.mds.nordian.com

[MDS NORDION LOGO]
  Science Advancing Health

May 25, 2005

Molecular Insight Pharmaceuticals Inc.
160 Second Street
Cambridge, Massachusetts
02142
USA

Dear Sirs:

RE:   AMENDMENT #1 TO AGREEMENT BETWEEN MDS NORDION, A DIVISION OF MDS (CANADA)
      INC. (SUCCESSOR TO MDS NORDION INC.) AND MOLECULAR INSIGHT PHARMACEUTICALS
      INC. DATED THE 14th DAY OF JUNE, 2004

Reference is made to the agreement between MDS Nordion and Molecular Insight
Pharmaceuticals Inc., dated the 14th day of June 2004 (the "Agreement").

In consideration of $1.00 and other valuable consideration the receipt of
sufficiency of which is hereby acknowledged, the parties desire to extend the
terms of the Agreement.

Section 16.1 of the Agreement shall be amended in its entirety and shall read as
follows:

                "The term of this Agreement shall commence upon the Effective
                Date, and unless terminated earlier pursuant to this Agreement,
                shall expire on December 31, 2006."

All other terms and conditions in this Agreement shall remain in full force and
effect.

The foregoing amendment shall be effective as of the date first written above.

If you agree with the foregoing, please execute this agreement in the space
provided below.

Sincerely,

                                          We agree this 25th day of May, 2005
MDS NORDION                               MOLECULAR INSIGHT PHARMACEUTICALS INC.

Per: /s/ Gerry Vantellingen               Per: /s/ John E. McCray
     ----------------------------                 ------------------------------
     Name: Gerry Vantellingen                     Name: John E. McCray
     Title: Vice President, Sales                 Title: Chief Operating Officer<PAGE>

                                                                   EXHIBIT 10.19

          AMENDED AND RESTATED MOLECULAR INSIGHT PHARMACEUTICALS, INC.
                           2006 EQUITY INCENTIVE PLAN

     1. PURPOSE AND EFFECTIVE DATE.

     (a) Purpose. The Molecular Insight Pharmaceuticals, Inc. 2006 Incentive
Stock and Awards Plan has two complementary purposes: (i) to attract and retain
outstanding individuals to serve as officers, directors, employees and
consultants and (ii) to increase shareholder value. The Plan will provide
participants incentives to increase shareholder value by offering the
opportunity to acquire shares of the Company's common stock, receive monetary
payments based on the value of such common stock, or receive other incentive
compensation, on the potentially favorable terms that this Plan provides.

     (b) Effective Date. This Plan will become effective, and Awards may be
granted under this Plan, on and after the Effective Date; provided that any
Awards granted prior to the date the Plan is approved by the Company
shareholders shall be contingent on such approval.

     2. DEFINITIONS. Capitalized terms used in this Plan have the following
meanings:

     (a) "Affiliate" means any entity that, directly or through one or more
intermediaries, is controlled by, controls, or is under common control with the
Company within the meaning of Code Sections 414(b) or (c), provided that, in
applying such provisions, the phrase "at least 50 percent" shall be used in
place of "at least 80 percent" each place it appears therein.

     (b) "Award" means a grant of Options, Stock Appreciation Rights,
Performance Shares, Performance Units, Restricted Stock, Restricted Stock Units,
or a Long-Term Incentive Award.

     (c) "Board" means the Board of Directors of the Company.

     (d) "Cause" means:

          (i) the failure of the Participant to perform any of his or her
     material duties to the Company, including, without limitation, breach of
     the Company's code of ethics, conflict of interest or employment policies;

          (ii) the Participant's conviction (including any pleas of guilty or
     nolo contendre) of any felony or other crime that the Committee reasonably
     determines adversely impacts the Participant's ability to continue
     performing services with the Company;

          (iii) any act or failure to act by the Participant (other than the
     Participant's resignation or retirement) which would reasonably be likely
     to have the effect of injuring the reputation, business or business
     relationships of the Company or impairing the Participant's ability to
     perform services for the Company;

          (iv) acts of theft, embezzlement, fraud, dishonesty, misrepresentation
     or falsification of documents or records involving the Company;

          (v) violation of any law or administrative regulation related to the
     Company's business and use of the Company's facilities or premises to
     conduct unlawful or unauthorized activities or transactions;

          (vi) conduct that could result in publicity reflecting unfavorably on
     the Company in a material way;

<PAGE>

          (vii) the Participant's improper use of the Company's confidential or
     proprietary information; or

          (viii) a breach of any material term of an employment agreement,
     confidentiality agreement, non-competition agreement and non-solicitation
     agreement or any other agreement between the Participant and the Company,
     after giving effect to the notification provisions, if any, and the
     mechanisms to remedy or cure a breach, if appropriate, as described in any
     such agreement.

The Committee shall determine whether conduct constituting "Cause" has occurred
for purposes of the Plan. For purposes of this definition, the term "Company"
includes any Affiliate and "Cause" is not limited to events that have occurred
before a Participant's termination, nor is it necessary that the Committee's
finding of "Cause" occur prior to such termination.

     (e) "Change of Control" means the occurrence of any one of the following
events:

          (i) A change in the ownership of the Company, which shall occur on the
     date that any one Person, or more than one Person Acting as a Group (as
     defined below), other than Excluded Person(s) (as defined below), acquires
     ownership of the stock of the Company that, together with the stock then
     held by such Person or group, constitutes more than fifty percent (50%) of
     the total fair market value of the stock of the Company. However, if any
     one Person or more than one Person Acting as a Group is considered to own
     more than fifty (50%) of the total fair market value of the stock of the
     Company, the acquisition of additional stock by the same Person or Persons
     is not considered to cause a Change of Control.

          (ii) A change in the effective control of the Company, which shall
     occur on the date that:

                    (A) Any one Person, or more than one Person Acting as a
               Group, other than Excluded Person(s), acquires (or has acquired
               during the twelve (12) month period ending on the date of the
               most recent acquisition by such Person or Persons) ownership of
               stock of the Company possessing thirty-five percent (35%) or more
               of the total voting power of the stock of the Company. However,
               if any one Person or more than one Person Acting as a Group is
               considered to own more than thirty-five percent (35%) of the
               total voting power of the stock of the Company, the acquisition
               of additional voting stock by the same Person or Persons is not
               considered to cause a Change of Control; or

                    (B) A majority of the members of the Company's Board of
               Directors is replaced during any twelve (12) month period by
               directors whose appointment or election is not endorsed by a
               majority of the members of the Company's Board of Directors prior
               to the date of the appointment or election.

          (iii) A change in the ownership of a substantial portion of the
     Company's assets, which shall occur on the date that any one Person, or
     more than one Person Acting as a Group, other than Excluded Person(s),
     acquires (or has acquired during the twelve (12) month period ending on the
     date of the most recent acquisition by such person or persons) assets from
     the Company that have a total Gross Fair Market Value (as defined below)
     equal to more than sixty percent (60%) of the total Gross Fair Market Value
     of all the assets of the Company immediately prior to such acquisition or
     acquisitions, other than an Excluded Transaction (as defined below).

                                        2

<PAGE>

     For purposes of this subsection (e):

               "Gross Fair Market Value" means the value of the assets of the
          Company, or the value of the assets being disposed of, as applicable,
          determined without regard to any liabilities associates with such
          assets.

               Persons will be considered to be "Acting as a Group" if they act
          in concert, provided that Persons will not be considered to be Acting
          as a Group solely because they purchase or own stock of the Company at
          the same time, or as a result of the same public offering, or solely
          because they purchase assets of the Company at the same time, or as a
          result of the same public offering, as the case may be. However,
          Persons will be considered to be Acting as a Group if they are owners
          of an entity that enters into a merger, consolidation, purchase or
          acquisition of assets, or similar business transaction with the
          Company.

               The term "Excluded Transaction" means any a transaction in which
          assets are transferred to: (A) a shareholder of the Company
          (determined immediately before the asset transfer) in exchange for or
          with respect to its stock; (B) an entity, fifty percent (50%) or more
          of the total value or voting power of which is owned, directly or
          indirectly, by the Company (determined after the asset transfer); (C)
          a Person, or more than one Person Acting as a Group, that owns,
          directly or indirectly, fifty percent (50%) or more of the total value
          or voting power of all the outstanding stock of the Company
          (determined after the asset transfer); or (D) an entity at least fifty
          percent (50%) of the total value or voting power of which is owned,
          directly or indirectly, by a Person described in clause (C)
          (determined after the asset transfer).

               The term "Excluded Person(s)" means (A) the Company or any of its
          Affiliates, (B) a trustee or other fiduciary holding securities under
          an employee benefit plan of the Company or any of its Affiliates, (C)
          an underwriter temporarily holding securities pursuant to an offering
          of such securities, or (D) a corporation owned, directly or
          indirectly, by the shareholders of the Company in substantially the
          same proportions as their ownership of stock in the Company.

          The term "Change of Control" as defined above shall be amended and
construed in accordance with any subsequent guidance, rules or regulations
promulgated by the Internal Revenue Service in construing the rules and
regulations applicable to Code Section 409A.

     (f) "Code" means the Internal Revenue Code of 1986, as amended. Any
reference to a specific provision of the Code includes any successor provision
and the regulations promulgated under such provision.

     (g) "Committee" means the Compensation Committee of the Board (or a
successor committee with the same or similar authority).

     (h) "Company" means Molecular Insight Pharmaceuticals, Inc., a
Massachusetts corporation, or any successor thereto.

     (i) "Director" means a member of the Board, and "Non-Employee Director"
means a Director who is not also an employee of the Company or its Subsidiaries.

     (j) "Disability" means the inability to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a
continuous period of at least twelve (12) months, as determined by the
Committee. The Committee may request such evidence of disability as it
reasonably determines.

                                        3

<PAGE>

     (k) "Effective Date" means the date on which the shares of the Company's
voting common stock are first sold to the public pursuant to an effective
registration statement filed by the Company under the Securities Act of 1933, as
amended from time to time.

     (l) "Exchange Act" means the Securities Exchange Act of 1934, as amended.
Any reference to a specific provision of the Exchange Act includes any successor
provision and the regulations and rules promulgated under such provision.

     (m) "Fair Market Value" means, per Share on a particular date, the last
sales price on such date on the NASDAQ Global Market (f/k/a NASDAQ National
Market), as reported in The Wall Street Journal, or if no sales of Stock occur
on the date in question, on the last preceding date on which there was a sale on
such market. If the Shares are not listed on the NASDAQ Global Market, but are
traded on a national securities exchange or in another over-the-counter market,
the last sales price (or, if there is no last sales price reported, the average
of the closing bid and asked prices) for the Shares on the particular date, or
on the last preceding date on which there was a sale of Shares on that exchange
or market, will be used. If the Shares are neither listed on a national
securities exchange nor traded in an over-the-counter market, the price
determined by the Committee, in its discretion, will be used.

     (n) "Long Term Incentive Award" means the right to receive a cash payment
to the extent Performance Goals are achieved as described in Section 10.

     (o) "Option" means the right to purchase Shares at a stated price for a
specified period of time. An Option may be an "Incentive Stock Option" that is
intended to qualify under Code Section 422 or a "Nonqualified Stock Option" that
is not intended to so comply.

     (p) "Participant" means an individual selected by the Committee to receive
an Award.

     (q) "Performance Goals" means any goals the Committee establishes that
relate to one or more of the following with respect to the Company or any one or
more of its Subsidiaries, Affiliates or other business units or divisions or
departments thereof:

          (i) earnings per share,

          (ii) return on average equity or average assets,

          (iii) earnings,

          (iv) earnings growth,

          (v) revenues,

          (vi) expenses,

          (vii) stock price,

          (viii) market share,

          (ix) return on sales, assets, equity or investment,

          (x) regulatory compliance,

          (xi) improvement of financial ratings,

          (xii) achievement of balance sheet or income statement objectives,

                                        4

<PAGE>

          (xiii) total shareholder return,

          (xiv) net operating profit after tax,

          (xv) pre-tax or after-tax income,

          (xvi) EBITDA or EBIT,

          (xvii) cash flow,

          (xviii) achievement of development, clinical or regulatory milestones,

          (xix) product sales, and

          (xx) business development activities.

Performance Goals may be absolute in their terms or measured against or in
relationship to other companies comparably, similarly or otherwise situated.
Such performance goals may be adjusted to exclude any one or more of (1)
extraordinary items, (2) gains or losses on the dispositions of discontinued
operations, (3) the cumulative effects of changes in accounting principles, (4)
the writedown of any asset, and (5) charges for restructuring and
rationalization programs. Notwithstanding the foregoing, in the case of Awards
that the Committee determines will not be considered "performance-based
compensation" under Code Section 162(m), the Committee may establish other
Performance Goals not listed in this Plan.

     (r) "Performance Shares" means the right to receive Shares to the extent
Performance Goals are achieved.

     (s) "Performance Unit" means the right to receive a payment valued in
relation to a unit that has a designated dollar value or the value of which is
equal to the Fair Market Value of one or more Shares, to the extent Performance
Goals are achieved.

     (t) "Person" has the meaning given in Section 3(a)(9) of the Exchange Act,
as modified and used in Sections 13(d) and 14(d) thereof.

     (u) "Plan" means this Molecular Insight Pharmaceuticals, Inc. 2006 Equity
Incentive Plan, as may be amended from time to time.

     (v) "Restricted Stock" means a Share that is subject to a risk of
forfeiture and restrictions on transfer.

     (w) "Restricted Stock Unit" means the right to receive a payment valued in
relation to a unit the value of which is equal to the Fair Market Value of one
Share.

     (x) "Retirement" means, unless otherwise specified in an Award agreement,
with respect to employee Participants, termination of employment from the
Company and its Affiliates (for other than Cause) on or after attainment of age
fifty-five (55) and completion of ten (10) years of continuous service with the
Company and its Affiliates, and with respect to Director Participants, means the
Director's resignation or failure to be re-elected following completion of the
Director's term.

     (y) "Rule 16b-3" means Rule 16b-3 as promulgated by the United States
Securities and Exchange Commission under the Exchange Act.

                                        5

<PAGE>

     (z) "Section 16 Participants" means Participants who are subject to the
provisions of Section 16 of the Exchange Act.

     (aa) "Share" means a share of Stock.

     (bb) "Stock" means the Common Stock of the Company, par value of $0.01 per
share.

     (cc) "Stock Appreciation Right" or "SAR" means the right to receive a
payment equal to the appreciation of the Fair Market Value of a Share during a
specified period of time.

     (dd) "Subsidiary" means any corporation, limited liability company or other
limited liability entity in an unbroken chain of entities beginning with the
Company if each of the entities (other than the last entities in the chain) owns
the stock or equity interest possessing more than fifty percent (50%) of the
total combined voting power of all classes of stock or other equity interests in
one of the other entities in the chain.

     3. ADMINISTRATION.

     (a) Committee Administration. The Committee shall administer the Plan. In
addition to the authority specifically granted to the Committee in this Plan,
the Committee has full discretionary authority to administer this Plan,
including but not limited to the authority to: (i) interpret the provisions of
this Plan, (ii) prescribe, amend and rescind rules and regulations relating to
this Plan, (iii) correct any defect, supply any omission, or reconcile any
inconsistency in any Award or agreement covering an Award in the manner and to
the extent it deems desirable to carry this Plan into effect and (iv) make all
other determinations necessary or advisable for the administration of this Plan.
All Committee determinations are final and binding.

     (b) Delegation to Other Committees or Officers. To the extent applicable
law permits, the Board may delegate to another committee of the Board, or the
Committee may delegate to one or more officers of the Company, any or all of the
authority and responsibility of the Committee. However, no such delegation is
permitted with respect to Awards made to Section 16 Participants at the time any
such delegated authority or responsibility is exercised. The Board also may
delegate to another committee of the Board consisting entirely of Non-Employee
Directors any or all of the authority and responsibility of the Committee with
respect to individuals who are Section 16 Participants. If the Board or the
Committee has made such a delegation, then all references to the Committee in
this Plan include such other committee or one or more officers to the extent of
such delegation.

     (c) Indemnification. The Company will indemnify and hold harmless each
member of the Committee, and each officer or member of any other committee to
whom a delegation under Section 3(b) has been made, as to any act done, or
determination made, with respect to this Plan or any Award to the maximum extent
that the law and the Company's by-laws permit.

     4. ELIGIBILITY. The Committee may designate any of the following as a
Participant from time to time: any officer or other employee of the Company or
its Affiliates, an individual that the Company or an Affiliate has engaged to
become an officer or employee, a consultant who provides services to the Company
or its Affiliates, or a Director, including a Non-Employee Director. The
Committee's designation of a Participant in any year will not require the
Committee to designate such person to receive an Award in any other year.

     5. TYPES OF AWARDS. Subject to the terms of this Plan, the Committee may
grant any type of Award to any Participant it selects, but only employees of the
Company or a Subsidiary may receive grants of Incentive Stock Options within the
meaning of Code Section 422. Awards may be granted alone or in addition to, in
tandem with, or in substitution for any other Award (or any other award granted
under another plan of the Company or any Affiliate).

                                        6

<PAGE>

     6. SHARES RESERVED UNDER THIS PLAN; AWARD LIMITS.

     (a) Plan Reserve. Subject to adjustment as provided in Section 14, an
aggregate of 2,300,000 Shares are reserved for issuance under this Plan. On
January 1 of each year beginning after the Effective Date, an additional number
of Shares equal to four percent (4%) of the number of Shares issued and
outstanding as of the immediately preceding December 31 shall become available
for issuance under this Plan. Notwithstanding the foregoing, the Company may
issue only 2,300,000 Shares upon the exercise of Incentive Stock Options.

     (b) Reduction of Share Reserve; Replenishment of Shares. The number of
Shares reserved for issuance under this Plan shall be reduced only by the number
of Shares actually delivered in payment or settlement of Awards. If Shares are
forfeited under an Award, or if Shares are issued under any Award and the
Company subsequently reacquires them pursuant to rights reserved upon the
issuance of the Shares, or if previously owned Shares are delivered to the
Company in payment of the exercise price or withholding taxes of an Award, then
such Shares may again be used for new Awards under this Plan under Section 6(a),
but such Shares may not be issued pursuant to Incentive Stock Options.

     (c) Participant Limitations. Subject to adjustment as provided in Section
14, no Participant may be granted Awards that could result in such Participant:

          (i) receiving a grant of Options for, and/or Stock Appreciation Rights
     with respect to, more than 500,000 Shares during any fiscal year of the
     Company;

          (ii) receiving an Award(s) of Restricted Stock and/or Restricted Stock
     Units relating to more than 250,000 Shares during any fiscal year of the
     Company;

          (iii) receiving an Award(s) of Performance Shares, and/or an Award(s)
     of Performance Units the value of which is based on the Fair Market Value
     of Shares, for more than 250,000 Shares during any fiscal year of the
     Company;

          (iv) receiving payment(s) under an Award of Performance Units, the
     value of which is not based on the Fair Market Value of Shares, for more
     than $1,500,000 during any fiscal year of the Company (regardless of the
     performance period to which it relates); or

          (v) receiving payment(s) under Long-Term Incentive Award(s) in any
     single fiscal year of the Company (regardless of the performance period to
     which it relates) of more than $1,500,000.

In all cases, determinations under this Section 6(c) should be made in a manner
that is consistent with the exemption for performance-based compensation that
Code Section 162(m) provides.

     (d) Limitation on Full-Value Awards. Not more than forty percent (40%) of
the total Shares that are reserved for grant may be granted or sold as Awards of
Restricted Stock, Restricted Stock Units, unrestricted grants of Shares, and any
other similar Awards ("Full-Value Awards") whose intrinsic value is not solely
dependent on appreciation in the price of Shares after the date of grant and
where the vesting of such awards is not subject to the attainment of Performance
Goals. Options, Stock Appreciation Rights, and Full-Value Awards subject to the
attainment of Performance Goals shall not be subject to, and shall not count
against, the limit described in the preceding sentence. If a Full-Value Award
subject to the limitation expires, is forfeited or otherwise lapses, the Shares
that were subject to the Award shall be restored to the total number of Shares
available for grant or sale as Full-Value Awards.

                                        7

<PAGE>

     7. OPTIONS. Subject to the terms of this Plan, the Committee will determine
all terms and conditions of each Option, including but not limited to: (i)
whether the Option is an Incentive Stock Option or a Nonqualified Stock Option;
(ii) the number of Shares subject to the Option; (iii) the exercise price, which
may not be less than the Fair Market Value of the Shares subject to the Option
as determined on the date of grant; (iv) the terms and conditions of exercise;
and (v) the term, except that an Option must terminate no later than ten (10)
years after the date of grant. In all other respects, the terms of any Incentive
Stock Option should comply with the provisions of Code Section 422 except to the
extent the Committee determines otherwise.

     (a) Non-Employee Directors. Notwithstanding the above, each Non-Employee
Director (if he or she continues to serve in such capacity) shall, on the day on
which such Non-Employee Director becomes a member of the Board, automatically be
granted a Non-Qualified Stock Option to purchase a number of shares of Stock
that is equal to 25,000 shares. In addition, each Non-Employee Director shall,
on the day following the annual meeting of shareholders in each subsequent year
such Non-Employee Director serves as a member of the Board, automatically be
granted a Non-Qualified Stock Option to purchase a number of shares of Stock
that is equal to 25,000 shares except that he or she will not receive his or her
second grant until the day following the second (2nd) annual meeting of
shareholders thereafter. Nonqualified Stock Options shall be automatically
granted to Non-Employee Directors under the Plan only for so long as the Plan
remains in effect and a sufficient number of Shares are available hereunder for
the granting of such Options. All share numbers set forth herein shall be
subject to adjustment in the manner provided in Section 14 herein. Nonqualified
Stock Options granted to Non-Employee Directors under the Plan are vested and
can only be exercised on and after the first anniversary of the date of grant.
Notwithstanding the foregoing, such Options shall terminate on the earlier of:
(a) ten (10) years after the date of grant; or (b) ninety (90) calendar days
after the Non-Employee Director ceases to be a director of the Company for any
reason, including as a result of the Non-Employee Director's death, disability
or retirement.

     8. STOCK APPRECIATION RIGHTS. Subject to the terms of this Plan, the
Committee will determine all terms and conditions of each SAR, including but not
limited to: (a) whether the SAR is granted independently of an Option or relates
to an Option; (b) the number of Shares to which the SAR relates; (c) the grant
price, provided that the grant price shall not be less than the Fair Market
Value of the Shares subject to the SAR as determined on the date of grant; (d)
the terms and conditions of exercise or maturity; (e) the term, provided that an
SAR must terminate no later than ten (10) years after the date of grant; and (f)
whether the SAR will be settled in cash, Shares or a combination thereof. If an
SAR is granted in relation to an Option, then unless otherwise determined by the
Committee, the SAR shall be exercisable or shall mature at the same time or
times, on the same conditions and to the extent and in the proportion, that the
related Option is exercisable and may be exercised or mature for all or part of
the Shares subject to the related Option. Upon exercise of any number of SAR,
the number of Shares subject to the related Option shall be reduced accordingly
and such Option may not be exercised with respect to that number of Shares. The
exercise of any number of Options that relate to an SAR shall likewise result in
an equivalent reduction in the number of Shares covered by the related SAR.

     9. PERFORMANCE AND STOCK AWARDS. Subject to the terms of this Plan, the
Committee will determine all terms and conditions of each award of Restricted
Stock, Restricted Stock Units, Performance Shares or Performance Units,
including but not limited to: (a) the number of Shares and/or units to which
such Award relates; (b) whether, as a condition for the Participant to realize
all or a portion of the benefit provided under the Award, one or more
Performance Goals must be achieved during such period as the Committee
specifies; (c) whether the restrictions imposed on Restricted Stock or
Restricted Stock Units are accelerated, and all or a portion of the Performance
Goals subject to an Award are deemed achieved, upon a Participant's death,
Disability or Retirement or such other circumstances as the Committee provides;
(d) with respect to Performance Units, whether to measure the value of each unit
in relation to a designated dollar value or the Fair Market Value of one or more

                                        8

<PAGE>

Shares; and (e) with respect to Restricted Stock Units and Performance Units,
whether to settle such Awards in cash, in Shares, or a combination thereof.

     10. LONG-TERM INCENTIVE AWARDS. Subject to the terms of this Plan, the
Committee will determine all terms and conditions of a Long-Term Incentive
Award, including but not limited to the Performance Goals, performance period,
the potential amount payable, and the timing of payment, subject to the
following: (a) the Committee must require that payment of all or any portion of
the amount subject to the Long-Term Incentive Award is contingent on the
achievement or partial achievement of one or more Performance Goals during the
period the Committee specifies, although the Committee may specify that all or a
portion of the Performance Goals subject to an Award are deemed achieved upon a
Participant's death, Disability or Retirement, or with respect to Long-Term
Incentive Awards not intended to qualify as performance-based compensation under
Code Section 162(m), such other circumstances as the Committee may specify; and
(b) the performance period must relate to a period of more than one fiscal year
of the Company.

     11. TRANSFERABILITY. Awards are not transferable other than by will or the
laws of descent and distribution, unless and to the extent the Committee allows
a Participant to: (a) designate in writing a beneficiary to exercise the Award
after the Participant's death; or (b) transfer an Award.

     12. TERMINATION AND AMENDMENT OF PLAN; AMENDMENT, MODIFICATION OR
CANCELLATION OF AWARDS.

     (a) Term of Plan. Unless the Board earlier terminates this Plan pursuant to
Section 12(b), this Plan will terminate on the date of the annual meeting of
shareholders that occurs in the fifth (5th) year following the year in which the
shareholders originally approve this Plan.

     (b) Termination and Amendment. The Board or the Committee may amend, alter,
suspend, discontinue or terminate this Plan at any time, subject to the
following limitations:

          (i) the Board must approve any amendment of this Plan to the extent
     the Company determines such approval is required by: (A) action of the
     Board, (B) applicable corporate law or (C) any other applicable law;

          (ii) shareholders must approve any amendment of this Plan to the
     extent the Company determines such approval is required by: (A) Section 16
     of the Exchange Act, (B) the Code, (C) the listing requirements of any
     principal securities exchange or market on which the Shares are then traded
     or (D) any other applicable law; and

          (iii) shareholders must approve any of the following Plan amendments:
     (A) an amendment to materially increase any number of Shares specified in
     Section 6(a) or the Participant limits specified in Section 6(c) (except as
     permitted by Section 14); or (B) an amendment that would diminish the
     protections afforded by Section 12(e).

     (c) Amendment, Modification or Cancellation of Awards. Subject to Section
12(e) and all other requirements of this Plan, the Committee may modify, amend
or cancel any Award, or waive any restrictions or conditions applicable to any
Award or the exercise of the Award, provided that any modification or amendment
that materially diminishes the rights of the Participant, or the cancellation of
the Award, shall be effective only if agreed to by the Participant or any other
person(s) as may then have an interest in the Award, but the Committee need not
obtain Participant (or other interested party) consent for the adjustment or
cancellation of an Award pursuant to the provisions of Section 14 or the
modification of an Award to the extent deemed necessary to comply with any
applicable law, the listing requirements of any principal securities exchange or
market on which the Shares are then traded, or to preserve favorable accounting
treatment of any Award for the Company. Notwithstanding the foregoing, unless
determined otherwise by the Committee, any such amendment shall be made in a

                                        9

<PAGE>

manner that will enable an Award intended to be exempt from Code Section 409A to
continue to be so exempt, or to enable an Award intended to comply with Code
Section 409A to continue to so comply.

     (d) Survival of Authority and Awards. Notwithstanding the foregoing, the
authority of the Board and the Committee under this Section 12 and to otherwise
administer the Plan will extend beyond the date of this Plan's termination. In
addition, termination of this Plan will not affect the rights of Participants
with respect to Awards previously granted to them, and all unexpired Awards will
continue in force and effect after termination of this Plan except as they may
lapse or be terminated by their own terms and conditions.

     (e) Repricing Prohibited. Notwithstanding anything in this Plan to the
contrary, and except for the adjustments provided in Section 14, neither the
Committee nor any other person may decrease the exercise price for any
outstanding Option or SAR after the date of grant nor allow a Participant to
surrender an outstanding Option or SAR to the Company as consideration for the
grant of a new Option or SAR with a lower exercise price.

     (f) Foreign Participation. To assure the viability of Awards granted to
Participants employed in foreign countries, the Committee may provide for such
special terms as it may consider necessary or appropriate to accommodate
differences in local law, tax policy or custom. Moreover, the Committee may
approve such supplements to, or amendments, restatements or alternative versions
of, this Plan as it determines is necessary or appropriate for such purposes.
Any such amendment, restatement or alternative versions that the Committee
approves for purposes of using this Plan in a foreign country will not affect
the terms of this Plan for any other country. In addition, all such supplements,
amendments, restatements or alternative versions must comply with the provisions
of Section 12(b)(ii) or (iii).

     (g) Code Section 409A. The provisions of Code Section 409A are incorporated
herein by reference to the extent necessary for any Award that is subject to
Code Section 409A to comply therewith.

     13. TAXES.

     (a) Withholding. Prior to the delivery of amounts payable (whether in cash
or Shares) or vesting of an Award under this Plan, the Company shall have the
right and power to deduct or withhold, or require a Participant or Beneficiary
to remit to the Company, an amount sufficient to satisfy any federal, state, and
local taxes that the Company determines is required to be withheld. If Shares
are deliverable upon exercise or payment of an Award, the Committee may permit
or require a Participant to satisfy all or a portion of the federal, state and
local withholding tax obligations arising in connection with such Award by
electing to (a) have the Company withhold Shares otherwise issuable under the
Award, (b) tender back Shares received in connection with such Award or (c)
deliver other previously owned Shares, in each case having a Fair Market Value
equal to the amount to be withheld. However, the amount to be withheld may not
exceed the total minimum federal, state and local tax withholding obligations
associated with the transaction to the extent needed for the Company to avoid an
accounting charge. If an election is provided, the election must be made on or
before the date as of which the amount of tax to be withheld is determined and
otherwise as the Committee requires.

     (b) No Guarantee of Tax Treatment. Notwithstanding any provisions of the
Plan, the Company does not guarantee to any Participant or any other Person with
an interest in an Award that any Award intended to be exempt from Code Section
409A shall be so exempt, nor that any Award intended to comply with Code Section
409A shall so comply, or any Option intended to qualify as an Incentive Stock
Option so qualifies, nor will the Company or any Affiliate indemnify, defend or
hold harmless any individual with respect to the tax consequences of any such
failure.

                                       10

<PAGE>

     14. ADJUSTMENT PROVISIONS; CHANGE OF CONTROL.

     (a) Adjustment of Shares. If any dividend or other distribution in the form
Shares, other securities, or other property or large non-recurring cash
dividend, recapitalization, stock split or reverse stock split, reorganization,
merger or consolidation, split-up or spin-off, combination, repurchase, or
exchange of Shares or other securities of the Company, issuance of warrants or
other rights to purchase Shares or other securities of the Company, or other
similar corporate transaction or event affects the Shares, then, subject to
Participants' rights under Section 14(c), the Committee shall, in such manner as
it may deem equitable to prevent dilution or enlargement of the benefits or
potential benefits intended to be made available under this Plan, adjust as
applicable: (i) the number and type of Shares subject to this Plan (including
the number and type of Shares described in Sections 6(a) and 6(c)) and which may
after the event be made the subject of Awards under this Plan, (ii) the number
and type of Shares subject to outstanding Awards, (iii) the grant, purchase, or
exercise price with respect to any Award, and (iv) to the extent such discretion
does not cause an Award that is intended to qualify as performance-based
compensation under Code Section 162(m) to lose its status as such, the
Performance Goals of an Award. In each case, with respect to Awards of Incentive
Stock Options, no such adjustment may be authorized to the extent that such
authority would cause this Plan to violate Code Section 422(b). Unless the
Committee determines otherwise, any such adjustment to an Award that is exempt
from Code Section 409A shall be made in manner that permits the Award to
continue to be so exempt, and any adjustment to an Award that is subject to Code
Section 409A shall be made in a manner that complies with the provisions
thereof. Further, the number of Shares subject to any Award payable or
denominated in Shares must always be a whole number. In the case of a stock
split or reverse stock split, if no action is taken by the Committee, the
proportionate adjustment contemplated by this subsection (a) shall nevertheless
be automatically made as of the date of such split.

     (b) Issuance or Assumption. Notwithstanding any other provision of this
Plan, and without affecting the number of Shares otherwise reserved or available
under this Plan, in connection with any merger, consolidation, acquisition of
property or stock, or reorganization, the Committee may authorize the issuance
or assumption of awards under this Plan upon such terms and conditions as it may
deem appropriate.

     (c) Change of Control. If the Participant has in effect an employment,
retention, change of control, severance or similar agreement with the Company or
any Affiliate that discusses the effect of a Change of Control on the
Participant's Awards, then such agreement shall control. In all other cases,
unless provided otherwise in an Award agreement, in the event of a Change of
Control:

          (i) The successor or purchaser in the Change of Control transaction
     may assume an Award or provide a substitute award with similar terms and
     conditions, and preserving the same benefits, as the Award it is replacing.
     In such event, if the Participant is terminated from employment or service
     on or within one year following the date of the Change of Control for any
     reason other than Cause, then:

                    (A) each Option or SAR shall become immediately and fully
               vested as of the date of such termination and the Option or SAR
               shall be exercisable, notwithstanding any provision to the
               contrary in the Award agreement, for a period of seventy-five
               (75) days following such termination of employment, but in no
               event after the tenth (10th) anniversary of the grant date;

                    (B) Restricted Stock and Restricted Stock Units that are not
               then vested shall vest upon the date of such termination;

                    (C) Performance Shares and/or Performance Units for which
               the performance period has not expired shall be deemed earned for
               a cash payment equal to the product of the value of the
               Performance Share and/or Performance

                                       11

<PAGE>

               Unit and a fraction, the numerator of which is the number of
               whole months that have elapsed from the beginning of the
               performance period to which the Award is subject to the date of
               such termination and the denominator of which is the number of
               whole months in the performance period;

                    (D) each holder of a Performance Share and/or Performance
               Unit that has been earned but not yet paid shall receive an
               amount of cash equal to the value of the Performance Share and/or
               Performance Unit; and

                    (E) all Long-Term Incentive Awards that are earned but not
               yet paid shall be paid, and all Long-Term Incentive Awards that
               are not yet earned shall be deemed to have been earned pro rata,
               as if the Performance Goals are attained as of the effective date
               of such termination, by taking the product of (A) the
               Participant's maximum award opportunity for the period to which
               the Award is subject, and (B) a fraction, the numerator of which
               is the number of whole months that have elapsed from the
               beginning of the performance period to which the Award is subject
               to the date of such termination and the denominator of which is
               the number of whole months in the performance period.

          (ii) If the successor or purchaser in the Change of Control
     transaction does not assume the Awards or issue replacement awards as
     provided in subsection (a), then immediately prior to the date of the
     Change of Control:

                    (A) each Option or SAR that is then held by a Participant
               who is employed by or in the service of the Company or an
               Affiliate shall become immediately and fully vested, and, if so
               determined by the Committee, all Options and SARs shall be
               cancelled on the date of the Change of Control in exchange for a
               cash payment equal to the excess of the Change of Control price
               of the Shares covered by the Option or SAR that is so cancelled
               over the purchase or grant price of such Shares under the Award;

                    (B) Restricted Stock and Restricted Stock Units that are not
               then vested shall vest;

                    (C) Performance Shares and/or Performance Units for which
               the performance period has not expired shall be cancelled in
               exchange for a cash payment equal to the product of the value of
               the Performance Share and/or Performance Unit and a fraction, the
               numerator of which is the number of whole months that have
               elapsed from the beginning of the performance period to which the
               Award is subject to the date of the Change of Control and the
               denominator of which is the number of whole months in the
               performance period;

                    (D) each holder of a Performance Share and/or Performance
               Unit that has been earned but not yet paid shall receive an
               amount of cash equal to the value of the Performance Share and/or
               Performance Unit; and

                    (E) all Long-Term Incentive Awards that are earned but not
               yet paid shall be paid, and all Long-Term Incentive Awards that
               are not yet earned shall be deemed to have been earned pro rata,
               as if the Performance Goals are attained as of the effective date
               of the Change of Control, by taking the product of (A) the
               Participant's maximum award opportunity for the period to which
               the Award is subject, and (B) a fraction, the numerator of which
               is the number of whole months that have elapsed from the
               beginning of the performance period to

                                       12

<PAGE>

               which the Award is subject to the date of the Change of Control
               and the denominator of which is the number of whole months in the
               performance period.

          Prior to or as of the date of the Change of Control, the Committee
shall determine the per share Change of Control price paid or deemed paid in the
Change of Control transaction. Except as otherwise expressly provided in any
agreement between a Participant and the Company or an Affiliate, if the receipt
of any payment by a Participant under the circumstances described above would
result in the payment by the Participant of any excise tax provided for in
Section 280G and Section 4999 of the Code, then the amount of such payment shall
be reduced to the extent required to prevent the imposition of such excise tax.

     15. MISCELLANEOUS.

     (a) Other Terms and Conditions. The grant of any Award may also be subject
to other provisions (whether or not applicable to the Award granted to any other
Participant) as the Committee determines appropriate, including, without
limitation, provisions for:

          (i) the payment of the purchase price of Options by delivery of cash
     or other Shares or other securities of the Company (including by
     attestation) having a then Fair Market Value equal to the purchase price of
     such Shares, or by delivery (including by fax) to the Company or its
     designated agent of an executed irrevocable option exercise form together
     with irrevocable instructions to a broker-dealer to sell or margin a
     sufficient portion of the Shares and deliver the sale or margin loan
     proceeds directly to the Company to pay for the exercise price;

          (ii) provisions giving the Participant the right to receive dividend
     payments or dividend equivalent payments with respect to the Shares subject
     to the Award (both before and after the Shares subject to the Award are
     earned, vested or acquired), which payments may be either made currently or
     credited to an account for the Participant which provides for the deferral
     of such amounts until a stated time, and may be settled in cash or Shares,
     as the Committee determines; provided that any Dividend Equivalents granted
     in connection with an Option, Stock Appreciation Right or other "stock
     right" within the meaning of Code Section 409A shall be set forth in a
     written arrangement that is separate from such Award, and to the extent the
     payment of such dividend equivalents is considered deferred compensation,
     such written arrangement shall comply with the provisions of Code Section
     409A;

          (iii) restrictions on resale or other disposition of Shares; and

          (iv) compliance with federal or state securities laws and stock
     exchange requirements.

     (b) Employment and Service. The issuance of an Award shall not confer upon
a Participant any right with respect to continued employment or service with the
Company or any Affiliate, or the right to continue as a Director. Unless
determined otherwise by the Committee, for purposes of the Plan and all Awards,
the following rules shall apply:

          (i) a Participant who transfers employment between the Company and its
     Affiliates, or between Affiliates, will not be considered to have
     terminated employment;

          (ii) a Participant who ceases to be a Non-Employee Director because he
     or she becomes an employee of the Company or an Affiliate shall not be
     considered to have ceased service as a Director with respect to any Award
     until such Participant's termination of employment with the Company and its
     Affiliates;

                                       13

<PAGE>

          (iii) a Participant who ceases to be employed by the Company or an
     Affiliate and immediately thereafter becomes a Non-Employee Director, a
     non-employee director of an Affiliate, or a consultant to the Company or
     any Affiliate shall not be considered to have terminated employment until
     such Participant's service as a director of, or consultant to, the Company
     and its Affiliates has ceased;

          (iv) a Participant employed by an Affiliate will be considered to have
     terminated employment when such entity ceases to be an Affiliate.

          Notwithstanding the foregoing, for purposes of an Award that is
subject to Code Section 409A, if a Participant's termination of employment or
service triggers the payment of compensation under such Award, then the
Participant will be deemed to have terminated employment or service upon a
"separation from service" within the meaning of Code Section 409A.

     (c) No Fractional Shares. No fractional Shares or other securities may be
issued or delivered pursuant to this Plan, and the Committee may determine
whether cash, other securities or other property will be paid or transferred in
lieu of any fractional Shares or other securities, or whether such fractional
Shares or other securities or any rights to fractional Shares or other
securities will be canceled, terminated or otherwise eliminated.

     (d) Unfunded Plan. This Plan is unfunded and does not create, and should
not be construed to create, a trust or separate fund with respect to this Plan's
benefits. This Plan does not establish any fiduciary relationship between the
Company and any Participant or other person. To the extent any person holds any
rights by virtue of an Award granted under this Plan, such rights are no greater
than the rights of the Company's general unsecured creditors.

     (e) Requirements of Law and Securities Exchange. The granting of Awards and
the issuance of Shares in connection with an Award are subject to all applicable
laws, rules and regulations and to such approvals by any governmental agencies
or national securities exchanges as may be required. Notwithstanding any other
provision of this Plan or any award agreement, the Company has no liability to
deliver any Shares under this Plan or make any payment unless such delivery or
payment would comply with all applicable laws and the applicable requirements of
any securities exchange or similar entity, and unless and until the Participant
has taken all actions required by the Company in connection therewith. The
Company may impose such restrictions on any Shares issued under the Plan as the
Company determines necessary or desirable to comply with all applicable laws,
rules and regulations or the requirements of any national securities exchanges.

     (f) Governing Law. This Plan, and all agreements under this Plan, will be
construed in accordance with and governed by the laws of the Commonwealth of
Massachusetts, without reference to any conflict of law principles. Any legal
action or proceeding with respect to this Plan, any Award or any award
agreement, or for recognition and enforcement of any judgment in respect of this
Plan, any Award or any award agreement, may only be heard in a "bench" trial,
and any party to such action or proceeding shall agree to waive its right to a
jury trial.

     (g) Limitations on Actions. Any legal action or proceeding with respect to
this Plan, any Award or any award agreement, must be brought within one year
(365 days) after the day the complaining party first knew or should have known
of the events giving rise to the complaint.

     (h) Construction. Whenever any words are used herein in the masculine, they
shall be construed as though they were used in the feminine in all cases where
they would so apply; and wherever any words are used in the singular or plural,
they shall be construed as though they were used in the plural or singular, as
the case may be, in all cases where they would so apply. Title of sections are
for general information only, and this Plan is not to be construed with
reference to such titles.

                                       14

<PAGE>

     (i) Severability. If any provision of this Plan or any award agreement or
any Award (i) is or becomes or is deemed to be invalid, illegal or unenforceable
in any jurisdiction, or as to any person or Award, or (ii) would disqualify this
Plan, any award agreement or any Award under any law the Committee deems
applicable, then such provision should be construed or deemed amended to conform
to applicable laws, or if it cannot be so construed or deemed amended without,
in the determination of the Committee, materially altering the intent of this
Plan, award agreement or Award, then such provision should be stricken as to
such jurisdiction, person or Award, and the remainder of this Plan, such award
agreement and such Award will remain in full force and effect.

              Adopted by the Board of Directors on August 17, 2006

                 Adopted by the Stockholders on August 31, 2006

                                       15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]